NEXGEL (NXGL) 10-K 31 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 30, 2021	Jun. 30, 2020
Document and Entity Information
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Entity Registrant Name	NEXGEL, INC.
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		102,893,779
Title of 12(g) Security	Common Stock, $0.001 par value
Entity Central Index Key	0001468929
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 0

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 32,000	$ 261,000
Accounts receivable, net	73,000	102,000
Inventory	233,000	113,000
Prepaid expenses and other current assets	25,000	37,000
Total current assets	363,000	513,000
Goodwill	311,000	0
Intangibles	47,000	0
Property and equipment, net	553,000	282,000
Operating lease - right of use asset	805,000	917,000
Other assets	178,000	178,000
Total assets	2,257,000	1,890,000
Current Liabilities:
Accounts payable	658,000	510,000
Accrued expenses and other current liabilities	90,000	27,000
Deferred Revenue	38,000	0
Convertible notes payable	59,000	0
Note payable, current portion	10,000	0
Note payable - PPP	147,000	0
Warrant liability	123,000	56,000
Operating lease liability, current portion	207,000	207,000
Total current liabilities	1,332,000	800,000
Operating lease liability, net of current portion	598,000	710,000
Notes payable, net of current portion	256,000	0
Total liabilities	2,186,000	1,510,000
Commitments and Contingencies
Preferred Stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 100,000,000 shares authorized; 99,331,579 and 57,505,208 shares issued and outstanding as of December 31, 2020 and 2019, respectively	99,000	57,000
Additional paid-in capital	2,474,000	561,000
Accumulated deficit	(2,502,000)	(238,000)
Total stockholders' equity	71,000	380,000
Total liabilities and stockholders' equity	$ 2,257,000	$ 1,890,000

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
BALANCE SHEETS
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	99,331,579	57,505,208
Common Stock, Shares, Outstanding	99,331,579	57,505,208

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
STATEMENTS OF OPERATIONS
Revenues, net	$ 674	$ 717
Cost of revenues	965	854
Gross (loss)/profit	(291)	(137)
Operating expenses
Selling, general and administrative	1,969	1,787
Total operating expenses	1,969	1,787
Loss from operations	(2,260)	(1,924)
Other income (expense)
Changes in fair value of warrant liability	(2)	1
Debt discount costs	(2)
Interest expense	(8)
Other income	8
Total other income (expense)	(4)	1
Net loss	$ (2,264)	$ (1,923)
Net loss per common share - basic	$ (0.03)	$ (0.14)
Net loss per common share - diluted	$ (0.03)	$ (0.14)
Weighted average shares used in computing net loss per common share - basic	78,895,052	13,570,585
Weighted average shares used in computing net loss per common share - diluted	78,895,052	13,570,585

STATEMENTS OF STOCKHOLDERS' EQU

STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-in Capital	Parent's Net Investment	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 0	$ 0	$ 281,000	$ 0	$ 281,000
Balance (in Shares) at Dec. 31, 2018	0
Net loss	$ 0	0	(1,685,000)	(238,000)	(1,923,000)
Transfer from parent	0	0	1,345,000	0	1,345,000
Reclassification of parent's net investment in connection with spin-off, June 21, 2019	0	(59,000)	59,000	0	0
Common stock distributed in connection with spin-off, June 21, 2019	$ 5,000	(5,000)	0	0	0
Common stock distributed in connection with spinoff, June 21, 2019 (in Shares)	5,005,211
Issuance of common stock	$ 52,000	621,000	0	0	673,000
Issuance of common stock (in shares)	52,499,997
Share-based compensation	$ 0	4,000	0	0	4,000
Balance at Dec. 31, 2019	$ 57,000	561,000	0	(238,000)	380,000
Balance (in Shares) at Dec. 31, 2019	57,505,208
Net loss	$ 0	0	0	(2,264,000)	(2,264,000)
Issuance of common stock	$ 27,000	1,343,000	0	0	1,370,000
Issuance of common stock (in shares)	26,522,500
Issuance of common stock for acquisition	$ 9,000	366,000	0	0	375,000
Issuance of common stock for acquisition (in shares)	9,375,000
Restricted stock vesting	$ 6,000	(6,000)	0	0	0
Restricted stock vesting (in shares)	5,928,871
Warrants issued for equity raising costs	$ 0	(65,000)	0	0	(65,000)
Beneficial conversion and warrant features of convertible debt	0	43,000	0	0	43,000
Share-based compensation	0	232,000	0	0	232,000
Balance at Dec. 31, 2020	$ 99,000	$ 2,474,000	$ 0	$ (2,502,000)	$ 71,000
Balance (in Shares) at Dec. 31, 2020	99,331,579

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Activities
Net loss	$ (2,264)	$ (1,923)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	50	67
Share-based compensation	232	4
Changes in fair value of warrant liability	2	(1)
Amortization of deferred financing costs	2	0
Changes in operating assets and liabilities:
Accounts receivable, net	29	(68)
Inventory	(99)	(12)
Prepaid expenses and other assets	10	189
Accounts payable	137	203
Accrued expenses and other liabilities	62	(273)
Deferred revenue	38	0
Net Cash Used in Operating Activities	(1,801)	(1,814)
Investing Activities
Purchase of equipment	(312)	0
Net Cash Used in Investing Activities	(312)	0
Financing Activities
Issuance of common stock, net of issuance costs	1,370	730
Proceeds from notes payable	414	0
Proceeds from convertible notes	100	0
Net distributions from Former Parent	0	1,345
Net Cash Provided by Financing Activities	1,884	2,075
Net Increase (Decrease) in Cash	(229)	261
Cash - Beginning of period	261	0
Cash - End of period	32	261
Non-cash Investing and Financing Activities
Common Shares issued for acquisition	375	0
Inventory acquired from acquisition	55	0
Accounts payable assumed from acquisition	13	0
Intangible assets acquired from acquisition	21	0
Beneficial conversion feature	43	0
Warrants issued as equity issuance cost	65	150
Accrued construction in progress	$ 0	$ 56

Description of Business, the Sp

Description of Business, the Spin-off and Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Description of Business, the Spin-off and Basis of Presentation
Description of Business, the Spin-off and Basis of Presentation	1. Description of Business NexGel, Inc. (the “Company” or “NexGel”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has historically served as a contract manufacturer supplying its gels to third parties who incorporate them into their own products. NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019. The Company is implementing a new strategy to become a consumer products business focused on proprietary branded products and white label opportunities. The Spin-Off On June 21, 2019, NexGel became an independent company through the pro rata distribution (“Spin-Off”) by Adynxx, Inc. (“Adynxx” and the “Parent”) in connection with the closing of a reverse merger between Adynxx, Inc. and Alliqua BioMedical, Inc., (“Adynxx”) of NexGel’s common stock for common stock of Parent. Adynxx, Inc. was previously known as Alliqua BioMedical, Inc. and subsequently changed its name to Adynxx, Inc. on May 3, 2019. The terms and conditions of the Spin-Off provided that each record holder of Parent stock as of April 22, 2019, received one share of NexGel common stock in book-entry form and resulted in the distribution of 5,005,211 shares of common stock of NexGel. Following the distribution (“Capitalization”), all existing operations were distributed to NexGel with the exception of a corporate lease for property in Yardley, Pennsylvania which was retained by Adynxx, Inc. Pursuant to the Spin-Off and in exchange for the 5,005,211 shares of common stock, NexGel assumed the following net liabilities from Parent as of June 21, 2019 ($ in thousands): Assets: Cash $ 186 Accounts receivable, net 72 Inventory 140 Prepaid expenses and other current assets 101 Property and equipment, net 155 Operating lease - right of use asset 976 Other assets 178 Total assets 1,808 Liabilities: Accounts payable (496) Accrued expenses and other current liabilities (395) Operating lease liability (976) Total liabilities (1,867) Net liabilities assumed in Spin-Off on June 21, 2019 $ (59) Basis of Presentation The balance sheet as of December 31, 2020 consists of the balances of NexGel as prepared on a stand-alone basis. The balance sheet as of December 31, 2019, and the statements of operations, stockholders’ equity, and cash flows were prepared on a “carve-out” basis for the periods and dates prior to the Spin-Off and include stand-alone results for the period subsequent to the date of Spin-Off. Prior to the separation, these financial statements were derived from the consolidated financial statements and accounting records of Adynxx, Inc. Prior to the Spin-Off, Adynxx used a centralized approach to cash management and financing its operations, including the operations of the Company. Accordingly, none of the cash of Adynxx have been attributed to the Company in the financial statements. Transactions between Adynxx and the Company were accounted for through Parent’s Net Investment. The expenses, including executive compensation, have been allocated by management based either on specific attribution of those expenses or, where necessary and appropriate, based on management’s best estimate of an appropriate proportional allocation.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2020
Going Concern
Going Concern	2. As of December 31, 2020, the Company had a cash balance of $32 thousand. For the year ended December 31, 2020, the Company incurred a net loss of $2.26 million and had a net usage of cash in operating activities of $1.80 million. In addition, the Company had a working capital deficit of $0.97 million as of December 31, 2020. From January 1, 2021 through March, 2021, the Company entered into Securities Purchase Agreements with certain accredited investors whereby we sold 3,562,500 shares of our common stock at a price per share equal to $0.08 for an aggregate purchase price of $285,000. On March 4, 2021, the Company received a second PPP Loan in the amount of $127 thousand under Phase II of the Paycheck Protection Program which commenced on January 13, 2021 and allowed certain businesses that received an initial PPP Loan to seek a second draw PPP Loan. On March 11, 2021, the Company entered into a securities purchase agreement (the "Auctus Purchase Agreement") with Auctus Fund, LLC, a Delaware limited liability company ("Auctus"), pursuant to which the Company issued to Auctus a senior secured convertible promissory note in the principal amount of $1,500,000 (the "Auctus Note"). The net proceeds received by the Company were $1,337,000 after deducting fees and expenses related to the transaction. Proceeds from the offerings are expected to be used for working capital, new product development and testing, and general business operations. The Company is in the process of expanding its customer base to increase revenue in order to alleviate the current going concern. Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products and proprietary medical devices. The Company has increased focused on sales and developing a sales pipeline for potential customers. This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation. Moving forward, the Company we will be raising additional capital and focusing on increasing revenues for the business to stabilize and become profitable. The Company will maintain and attempt to grow the existing contract manufacturing business. The Company plans to continue building and developing its catalog of consumer products for sale to branding partners. The Company products have the ability to deliver a wide range of compounds. Thirdly, we will use our in-house capabilities to create and test market additional branded products. These products will be target marketed and sold online through social media, television and online market places. The Company expects to continue incurring losses for the near-term future and may need to raise additional capital to support ongoing operations. The ability of the Company to continue to operate as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve profitable operations. Management is evaluating various options to raise capital to fund the Company’s working capital requirements through equity offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern. On January 30, 2020, the World Health Organization declared the coronavirus outbreak a "Public Health Emergency of International Concern" and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to date, the Company could experience declining revenue, labor and supply shortages, or difficulty in raising additional capital. Our concentrations with a few customers and one supplier make it reasonably possible that we are vulnerable to the risk of a near-term severe impact. Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long lived assets.

Significant Accounting Policies

Significant Accounting Policies and Estimates	12 Months Ended
	Dec. 31, 2020
Significant Accounting Policies and Estimates
Significant Accounting Policies and Estimates	3. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions include allowance for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates. Cash Cash include cash on hand and highly liquid investments having an original maturity of three months or less. Accounts receivable, net Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $1 thousand as of December 31, 2020 and $2 thousand as of December 31, 2019. Inventory Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence or shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value. The balance is made up of raw materials, work-in-progress, and finished goods of $190 thousand, $22 thousand and $21 thousand on December 31, 2020, respectively, and was $113 thousand of raw material on December 31, 2019. As a contract manufacturer, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process. There were no work in progress or finished goods inventories as of December 31, 2019. Property and equipment, net Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets ’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred. Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life. The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the period of disposal and the resulting gains and losses are included in the results of operations during the same period. Impairment of Long-Lived Assets We review the recoverability of our long-lived assets, including equipment and right-of-use assets, when events or changes in circumstances occur that indicate that the carrying value of the asset, or asset group, may not be recoverable. Events or circumstances that might cause management to perform impairment testing include, but are not limited to, significant underperformance relative to historical or projected future operating results of the asset or asset group, significant changes in the manner or use of assets or the strategy for our overall business; and significant negative industry or economic trends. If indicators of potential impairment are present, management performs a recoverability test and, if necessary, records an impairment loss. If the total estimated future undiscounted cash flows to be generated from the use and ultimate disposition of an asset or asset group is less than its carrying value, an impairment loss is recorded in the Company’s results of operations, measured as the amount required to reduce the carrying value to fair value. Fair value is determined in accordance with the best available information per the hierarchy described under Fair Value Measurements below. For example, the Company would first seek to identify quoted prices or other observable market data. If observable data is not available, Management would apply the best available information under the circumstances to a technique such as a discounted cash flow model to estimate fair value. Impairment analysis involves estimates and the use of assumptions due to the inherently judgmental nature of forecasting long-term estimated inflows and outflows resulting from the use and ultimate disposition of an asset, and determining the ultimate useful lives of assets. Actual results may differ from these estimates using different assumptions, which could materially impact the results of an impairment assessment. Prepaid expenses and other current assets Prepaid expenses and other current assets is recorded at historical cost and is primarily made up of $16 thousand and $18 thousand of prepaid insurance, and $9 thousand and $17 thousand general prepaid expenses and other current assets in the years ended December 31, 2020 and 2019 respectively. Other Assets Other Assets is recorded at historical costs, and as of December 31, 2020, the balance is entirely made up of spare parts for manufacturing equipment. Other assets are stated at cost and are not subject to depreciation, until such time that they are placed into service and the part that is being replaced is disposed. Fair value measurements The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: Level 1 —Quoted prices for identical assets or liabilities in active markets. Level 2 —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable. The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments. Warrant Liability Warrants to purchase common stock were issued in connection with equity financing raises, which occurred on December 24, 2020, March 18, 2020, September 10, 2019 and November 6, 2019. The fair values of the warrants are estimated as of the date of issuance and again at each period end using a Black-Scholes option valuation model. At issuance, the fair value of the warrant is recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations. Revenue recognition On January 1, 2018, the Company adopted Accounting Standards Codification ( “ ASC ” ) Topic 606, Revenue from Contracts with Customers ( “ ASC 606 ” ). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing accounting principles generally accepted in the United States of America (“U.S. GAAP”) including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required. The Company recognizes revenue predominately from one type of revenue, contract manufacturing. Revenue from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. The Company’s customers consist of other life sciences companies and revenues are concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial. As of December 31, 2020 and 2019, the Company did not have any contract assets or contract liabilities from contracts with customers. As of December 31, 2020 and December 31, 2019, there were no remaining performance obligations that the Company had not satisfied. Share-based compensation On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan (the "2019 Plan"). The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights ("SARs"), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initial reserved a total of 2,000,000 shares of the Company's common stock for awards under the 2019 Plan. Effective as of May 26, 2020, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 2,000,000 shares of common stock to 17,000,000 shares of common stock all of which may be delivered pursuant to incentive stock options. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may be granted to an executive officer during any calendar year is 500,000 shares of common stock. The Company’s 2019 Long-Term Incentive Plan provides certain employees, contractors and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur. In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018‑07, Compensation - Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting . These amendments expand the scope of Topic 718, Compensation - Stock Compensation , to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This new standard is effective for the Company on January 1, 2020. The Company early adopted this new standard in the third quarter of 2019 and it did not have material impact to its condensed financial statements. Income taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. Segment reporting The Company operates in one business segment as a contract manufacturer of aqueous polymer hydrogels. As a result, the Company’s operations are a single reportable segment, which is consistent with the Company’s internal management reporting. Comprehensive loss Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all periods presented, Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (the "FASB”) established ASC Topic 842, Leases , by issuing Accounting Standards Update (“ASU”) No. 2016‑02, which requires lessees to recognize operating leases on the balance sheet and disclose key information about leasing arrangements. ASC Topic 842 was subsequently amended by ASU No. 2018‑01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018‑10, Codification Improvements to Topic 842, Leases; and ASU No. 2018‑11, Targeted Improvements . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the new standard on leases on January 1, 2019. The Company currently recognizes an operating lease right-of-use asset and a corresponding lease liability on its condensed balance sheet. The Company also applies the following accounting policies related to this standard: · The Company does not recognize ROU assets and liabilities for leases with a term of 12 months or less; and · The Company does not separate lease and non-lease components in the Company ’ s lease contracts. Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Financial Instruments— Credit Losses In June 2016, the FASB issued ASU No. 2016‑13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In November 2019, the FASB issued ASU No. 2019‑10 Financial Instruments — Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842). The update allows the extension of the initial effective date for entities which have not yet adopted ASU No. 2016‑02. The standard is effective for annual reporting periods beginning after December 15, 2022, with early adoption permitted for annual reporting periods beginning after December 15, 2018. Entities will apply the standard’s provisions by recording a cumulative effect adjustment to retained earnings. The Company has not yet adopted ASU 2016‑13 and currently assessing the impact of this new standard on its financial statements. Collaborative Arrangements In November 2018, the FASB issued ASU 2018‑18, Collaborative Arrangements (Topic 808). This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers (“ASU 2018‑18”) . The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018‑18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s financial statements as the Company does not have any collaborative agreements. However, there is a potential for the Company to enter into collaborative agreements in the future, as it expands into consumer markets. Fair Value Measurement—Disclosure Framework In August 2018, the FASB issued ASU No. 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018‑13”), which amends ASC Topic 820, Fair Value Measurements. ASU 2018‑13 modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The effective date is the first quarter of fiscal year 2021, with early adoption permitted for the removed disclosures and delayed adoption permitted until fiscal year 2021 for the new disclosures. The removed and modified disclosures will be adopted on a retrospective basis and the new disclosures will be adopted on a prospective basis. The Company has not yet adopted ASU 2018‑13 and currently assessing the impact of this new standard on its financial statements.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2020
Acquisition
Acquisition	4. On May 29, 2020, the Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) whereby the Company purchased all of the outstanding equity securities of Sport Defense LLC, a Delaware limited liability company (“Sports Defense”), from the members of Sport Defense (the “Sellers”). Subsequent to the Closing Date, Sport Defense is a wholly-owned subsidiary of the Company. Sport Defense is a marketing and distribution company that leverages the unique benefits of ultra-gentle, high-water content hydrogels, manufactured by the Company, to build brands that treat various ailments of the skin caused by athletic training, such as blisters, turf burns, scrapes and skin irritations. Under the terms of the Purchase Agreement, the purchase price paid to the Sellers was an aggregate of $375 thousand (the “Purchase Price”) which was paid by the Company through the issuance of an aggregate of 9,375,000 shares of the Company’s common stock, par value $0.001 (the “Shares”), which equates to a per share purchase price of $0.04. The Shares are “restricted securities” as such term is defined by Rule 144 promulgated under the Securities Act of 1933, as amended. Adam Levy, the Company’s Chief Executive Officer and Chief Financial Officer, and Nachum Stein, a member of the Company’s Board of Directors (the “Board”), were each members of Sport Defense and part of the Sellers. Mr. Levy received 1,546,875 of the Shares and Mr. Stein received 3,187,500 of the Shares. Due to the potential conflict of interest that existed because of Messrs. Levy and Stein’s partial ownership of Sport Defense, the Board obtained an independent investment bank to prepare a valuation report with respect to Sport Defense. This valuation report supported the Purchase Price. Also, Mr. Stein recused himself from the vote of the Board regarding the approval to purchase Sport Defense. The Purchase Agreement and the Sport Defense acquisition were not subject to approval by the shareholders of the Company. The Purchase Agreement contained minimal representations and warranties regarding Sport Defense and certain limited representations and warranties regarding the Company and the Sellers. The provisional fair value of the purchase consideration issued to the Seller was allocated to the net tangible assets acquired. The Company accounted for the Sports Defense acquisition as the purchase of a business under GAAP under the acquisition method of accounting, and the assets and liabilities acquired were recorded as of the acquisition date, at their respective fair values and consolidated with those of the Company. The fair value of the net assets acquired was approximately $375 thousand. The excess of the aggregate fair value of the net tangible assets has been allocated to goodwill. The Company is currently in the process of completing the preliminary purchase price allocation as an acquisition of certain assets. The final purchase price allocation for Sports Defense’s will be included in the Company’s financial statements in future periods. The table below shows preliminary analysis for the Sports Defense acquisition: Provisional Purchase Consideration at preliminary fair value: Purchase price $ 375 Amount of consideration $ 375 Assets acquired and liabilities assumed at preliminary fair value Inventories 21 Product/Technology related intangibles 31 Marketing related intangibles 8 Customer related intangibles 17 Accounts payable and accrued expenses (13) Other liabilities — Net tangible assets acquired $ 64 Total net assets acquired $ 64 Consideration paid 375 Preliminary goodwill $ 311 The unaudited pro-forma results of operations are presented for information purposes only. The unaudited pro-forma results of operations are not intended to present actual results that would have been attained had the Sports Defense acquisition been completed as of January 1, 2019 or to project potential operating results as of any future date or for any future periods. For the Year Ended December 31, 2020 2019 Revenues, net $ 691 $ 760 Net loss allocable to common shareholders $ (2,254) $ (1,963) Net loss per share $ (0.03) $ (0.09) Weighted average number of shares outstanding 86,707,552 22,945,585

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases
Leases	5. The Company has one operating lease for a commercial manufacturing facility and administrative offices located in Langhorne, Pennsylvania that runs through January 2026. The right-of-use asset and lease liability from this operating lease were recognized in the opening balance sheet as of January 1, 2019 and are based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rate. The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2020 ($ in thousands): Operating Lease Maturity of Lease Liability Liability 2021 $ 207 2022 207 2023 207 2024 207 2025 207 Thereafter 18 Total undiscounted operating lease payments $ 1,053 Less: Imputed interest (248) Present value of operating lease liability $ 805 Weighted average remaining lease term 5.0 years Weighted average discount rate % Total operating lease expense for the year ended December 31, 2020 and 2019 was $207 thousand, and is recorded in cost of goods sold and selling, general and administrative expenses on the statement of operations. For the year ended December 31, 2019, the Company recorded lease expense under Accounting Standards Codification Topic 840, Leases , and recognized $207 thousand, which was recorded in cost of goods sold and selling, general and administrative expenses. Supplemental cash flows information related to leases was as follows ($ in thousands): December 31, 2019 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating lease $ 207 Right-of-use asset obtained in exchange for lease obligation: Operating lease $ 805

Inventory

Inventory	12 Months Ended
	Dec. 31, 2020
Inventory
Inventory	6. Inventory consists of the following ($ in thousands): December 31, December 31, 2020 2019 Raw materials $ 190 $ 113 Work-in-progress 22 — Finished goods 21 — 233 113 Less: Inventory reserve for excess and slow moving inventory — — Total $ 233 $ 113 As a contract manufacturer, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property and Equipment, Net
Property and Equipment, Net	7. Property and Equipment, Net Property and equipment consist of the following ($ in thousands): Useful Life December 31, December 31, (Years) 2020 2019 Machinery and equipment 3 - 10 $ 2,894 $ 2,893 Office furniture and equipment 3 - 10 49 49 Leasehold improvements 6 228 228 Construction in progress N/A 461 150 3,632 3,320 Less: accumulated depreciation and amortization (3,079) (3,038) Property and equipment, net $ 553 $ 282 Depreciation expense for the year ended December 31, 2020 and 2019 was $42 thousand and $67 thousand, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2020
Intangible Assets
Intangible Assets	8. The following provides a breakdown of identifiable intangible assets as of December 31, 2020: December 31, 2020 Product/Technology Related Identifiable intangible assets, gross $ 31 Accumulated amortization (6) Product/Technology Related identifiable intangible assets, net 25 Marketing Related Customer related intangible asset, gross 17 Tradename related intangible asset, gross 7 Accumulated amortization (2) Marketing related identifiable intangible assets, net 22 Total Identifiable intangible assets, net $ 47 In connection with the acquisitions of Sports Defense, the Company identified intangible assets of $55 thousand representing technology related and customer related intangibles. These assets are being amortized on a straight-line basis over their weighted average estimated useful life of 2.6 years and amortization expense amounted to $8 thousand for the year ended December 31, 2020. As of December 31, 2020, the estimated annual amortization expense for each of the next five fiscal years is as follows: 2021 $ 14 2022 14 2023 8 2024 3 2025 2 Thereafter 6 Total $ 47

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	9. Accrued expenses and other current liabilities consist of the following ($ in thousands): December 31, December 31, 2020 2019 Salaries, benefits and incentive compensation $ 43 $ 14 Professional fees — — Other 47 14 Total accrued expenses and other current liabilities $ 90 $ 28

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2020
Common Stock
Common Stock	10. On September 10, 2019, the Company entered into a Stock Purchase Agreement to issue and sell shares of the Company’s common stock, par value $0.001 per share, in a private placement offering to accredited investors for an aggregate of up to $175 on the initial closing date, and an aggregate of up to $575 of shares of common stock on a subsequent closing date at a price per share equal to $0.053525. On September 10, 2019, certain accredited investors purchased 3,269,500 shares of the Company’s common stock that resulted in cash proceeds of $175 thousand. For their commitment to invest the $175 thousand, the two shareholders who invested in the September 10, 2019 private placement each became a member of the Company’s Board of Directors and gained control of the Company. Their investments carried full ratchet protection on the purchase price per share of $0.053525 because the actual price of the shares in the September 10, 2019 private placement was undetermined at that time. The final price per share of the September 10, 2019 private placement, which was governed by a term sheet dated August 27, 2019, was ultimately determined to be $0.014. On November 6, 2019 and pursuant to the Stock Purchase Agreement, the Company issued an additional 39,999,998 shares of its common stock, par value $0.001 per share, in a private placement offering to accredited investors valued at $0.014 per share and raised $560 thousand. Proceeds from this offering are expected to be used for working capital and general business operations. Upon the completion of the secondary offering on November 6, 2019 that provided for the settlement of the ratchet protection, there was a reclassification from Additional paid-in capital to Common stock for the par value of the 9,230,500 additional shares that were issued to the two shareholders who invested in the September 10, 2019 private placement. Issuance costs related to the September 10, 2019 and November 6, 2019 private placements totaled $5 dollars in legal fees and $56 thousand related to warrants issued as an equity issuance cost. See Note 14– Warrant Liability. Share issuances From February 6, 2020 through March 20, 2020, the Company entered into Securities Purchase Agreements with certain accredited investors whereby we sold 15,500,000 shares of our common stock at a price per share equal to $0.04 for an aggregate purchase price of $620,000. Proceeds from this offering are expected to be used for working capital, new product development and testing, and general business operations. The placement agent for the private placement and is entitled to receive a total fee equal to 6% of the total gross proceeds and warrants to purchase the number of shares of Common Stock equal to 10% of the number of shares of Common Stock issued to the Investors, for such services rendered. The warrants are exercisable for 3 years at an exercise price equal to $0.04. From July 30, 2020 through August 14, 2020, the Company entered into Securities Purchase Agreements with certain accredited investors whereby we sold 6,585,000 shares of our common stock at a price per share equal to $0.06 for an aggregate purchase price of $395,100. From October 13, 2020 through December 24, 2020, the Company entered into Securities Purchase Agreements with certain accredited investors whereby we sold 4,437,500 shares of our common stock at a price per share equal to $0.08 for an aggregate purchase price of $355,000. Proceeds from this offering are expected to be used for working capital, new product development and testing, and general business operations. On February 10, 2020, a majority of our stockholder through a written consent approved the following: an amendment to our Restated Certificate of Incorporation which will increase the number of authorized shares of Common Stock from 100,000,000 shares of Common Stock to 3,000,000,000 shares of Common Stock and (ii) an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our Common Stock by a ratio of not less than one-for-thirty and not more than one-for-one hundred, with the exact number to be set at a whole number within this range to be determined by our board of directors in its sole discretion and to authorize our board of directors to implement the reverse stock split by filing an amendment to our Amended and Restated Certificate of Incorporation. On May 26, 2020, the Company filed an amendment to the certificate of incorporation to increase the number of the Company's authorized shares of common stock from 100,000,000 shares of common stock to 3,000,000,000 shares of common stock. The reverse stock split has not been effected as of date of the filing of this Form 10-K. For more information on these amendments, please see the Company's Definitive Information Statement on Schedule 14C filed with the SEC on March 16, 2020. On February 17, 2020, the Company granted certain equity awards to the members of the Company's Board of Director with the following terms: each of Messrs. Stefansky and Stein received two annual awards of stock options equal to $40,000 of the Company's common stock, granted under the Company 2019 Long-Term Incentive Plan (the "Incentive Plan"), with (i) the first grant being the right to purchase up to 2,857,141 shares of the Company's common stock at a per share exercise price of $0.014 with one-half of such option vesting on March 31, 2020 and the remaining one-half vesting in equal installments on June 30, 2020 and September 30, 2020, respectively, and with an acceleration of any unvested options upon the departure of applicable Board member from the Board for any reason and (ii) the second grant being the right to purchase up to a number of shares of the Company's common stock equal to $40,000 divided by the Fair Market Value (as defined in the Incentive Plan) of the Company's common stock as of October 10, 2020 at a per share exercise price equal to Fair Market Value of the Company's common stock as of October 10, 2020 with one-fourth of such option vesting on each of December 31, 2020, March 31, 2021, June 30, 2021 and September 30, 2021, respectively, and with an acceleration of any unvested options upon the departure of applicable Board member from the Board for any reason. On February 17, 2020, the Company granted a restricted stock award of 5,928,571 shares of the Company's common stock to the Company's Chief Executive Officer and Chief Financial Officer, Adam Levy, with the following vesting terms: (i) 3/12 th of such shares vested as of February 17, 2020; (ii) 1/12 th of such shares vest on each of the eight months following February 17, 2020 and (iii) all remaining shares vest on September 10, 2020. In November 2020, the Company issued 5,928,871 shares to our Chief Executive Officer upon the vesting of the restricted stock awards (See Note 12). At December 31, 2020, the Company has reserved common stock for issuance in relation to the following: Share-based compensation plan 17,000,000 Warrants to purchase common stock 9,172,500

Net Loss Per Common Share

Net Loss Per Common Share	12 Months Ended
	Dec. 31, 2020
Net Loss Per Common Share
Net Loss Per Common Share	11. a. Basic loss per share data is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during the period. Dilutive common-equivalent shares consist of shares that would be issued upon the exercise of stock options and other common stock equivalents, computed using the treasury stock method. The number of shares that may be issued for share-based payment awards under the Company’s 2019 Long-Term Incentive Plan are excluded from the calculation of weighted average dilutive common shares for the year ended December 31, 2019, to the extent they are issued and outstanding, because their effect would be anti-dilutive. b. On June 21, 2019, the date of consummation of the Spin-Off, 5,005,211 shares of the Company’s Common Stock, par value $0.001 per share, was distributed to Adynxx shareholders of record as of April 22, 2019. This share amount is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off as no common stock was outstanding prior to the date of the Spin-Off. For the year ended December 31, 2019 calculations, these shares are treated as issued and outstanding from January 1, 2019 for purposes of calculating historical basic and diluted earnings per share. The financial statements for 2019 were adjusted herein to reflect the subsequent consummation of the spinout and the inclusion of basic and diluted earnings per share, as described above, consistent with that of the year ended December 31, 2019.

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2020
Share-based Compensation
Share-based Compensation	12. On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan (the “2019 Plan”). The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initially reserved a total of 2,000,000 shares of the Company’s common stock for awards under the 2019 Plan. Effective as of May 26, 2020, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 2,000,000 shares of common stock to 17,000,000 shares of common stock all of which may be delivered pursuant to incentive stock options., all of which may be delivered pursuant to incentive stock options. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may be granted to an executive officer during any calendar year is 500,000 shares of common stock. Incentive stock options In August 2019, pursuant to the terms of the 2019 Plan, the Company awarded options to purchase an aggregate of 1,000,000 shares of common stock to two of its employees and one contractor. Pursuant to the terms of the option agreements, 50% of such options vested on the date of grant, and the remaining 50% of such options will vest on the first anniversary of the date of grant. The term of the options is ten years. On February 17, 2020, the Company granted certain equity awards to the members of the Company's Board of Director with the following terms: each of Messrs. Stefansky and Stein received two annual awards of stock options equal to $40,000 of the Company's common stock, granted under the Company 2019 Long-Term Incentive Plan (the "Incentive Plan"), with (i) the first grant being the right to purchase up to 2,857,141 shares of the Company's common stock at a per share exercise price of $0.014 with one-half of such option vesting on March 31, 2020 and the remaining one-half vesting in equal installments on June 30, 2020 and September 30, 2020, respectively, and with an acceleration of any unvested options upon the departure of applicable Board member from the Board for any reason and (ii) the second grant being the right to purchase up to a number of shares of the Company's common stock equal to $40,000 divided by the Fair Market Value (as defined in the Incentive Plan) of the Company's common stock as of October 10, 2020 at a per share exercise price equal to Fair Market Value of the Company's common stock as of October 10, 2020, which the Board determined to be $0.06 and equates to 666,667 shares underlying each of the second grants, with one-fourth of such option vesting on each of December 31, 2020, March 31, 2021, June 30, 2021 and September 30, 2021, respectively, and with an acceleration of any unvested options upon the departure of applicable Board member from the Board for any reason. In May 2020 and July 2020, pursuant to the terms of the 2019 Plan, the Company awarded options to purchase an aggregate of 5,325,000 shares of common stock to two of its employees and one contractor. Pursuant to the terms of the option agreements, 325,000 of the options vested on the date of grant, and of the 5,000,000 options, 10% of such options vested on the date of grant, and the remaining of such options will vest upon meeting established criteria. The term of the options is ten years. The following table contains information about the 2020 Plan as of December 31, 2020: Awards Awards Reserved for Available for Issuance Awards Issued Grant 2019 Plan 17,000,000 13,705,949 3,294,051 The following table summarizes the Company’s incentive stock option activity and related information for the period ended December 31, 2020: Weighted Weighted Average Number of Average Contractual Options Exercise Price Term in Years Outstanding at June 21, 2019 — — — Granted 1,000,000 $ 0.053525 10.0 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2019 1,000,000 $ 0.053525 9.6 Granted 12,705,949 $ 0.0291 10.0 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2020 13,705,949 $ 0.027736 Exercisable at December 31, 2020 12,455,949 $ 0.024498 As of December 31, 2020, vested outstanding stock options had $681 thousand intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock. As of December 31, 2020, there was approximately $72 thousand of total unrecognized share-based compensation related to unvested stock options, which the Company expects to recognize over the next 12 months. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following assumptions were used to calculate share-based compensation expense for year ended December 31, 2020: Volatility 136.81% - 171.47 % Risk-free interest rate 0.29% - 1.39 % Dividend yield 0.0 % Expected term 5.0 - 6.0 years The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two. Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted-average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage. Restrictive stock awards On February 17, 2020, the Company granted a restricted stock award of 5,928,571 shares of the Company’s common stock to the Company’s Chief Executive Officer and Interim Chief Financial Officer, Adam Levy, with the following vesting terms: (i) 3/12 th of such shares vested as of February 17, 2020; (ii) 1/12 th of such shares vest on each of the eight months following February 17, 2020 and (iii) all remaining shares vest on September 10, 2020. On March 8, 2021, the Company granted a restricted stock award of 1,383,333 shares of the Company’s common stock to the Adam Levy for his service as our Chief Executive Officer and Chief Financial Officer from October 1, 2020 through September 30, 2021, all of which shares vested immediately. Weighted Average Number of Grant Date Units Fair Value Granted 7,311,904 $ 0.023 Exercised and converted to common shares (5,928,571) 0.014 Forfeited — — Outstanding at December 31, 2020 1,383,333 $ 0.060 Exercisable at December 31,2020 345,833 $ 0.060 Under ASC 718, Compensation-Stock Compensation ("ASC 718"), the Company has measured the value of its February 2020 award as if it were vested and issued on the grant date with a value of $83 thousand based on the closing price of the Company's stock at the grant date of the RSU Grant ($0.014 per share). An additional issuance of 1,383,333 shares were granted based on a closing price of the closing price of the Company's stock at the grant date of the RSU Grant ($0.06 per share). As of December 31, 2020, there was approximately $63 thousand of total unrecognized share-based compensation related to restricted stock awards, which the Company expects to recognize over the next 9 months. Compensation expense will be recognized ratably over the total vesting schedule. The Company will periodically adjust the cumulative compensation expense for forfeited awards. Stock based compensation of $103 thousand has been recorded for the year ended December 31, 2020. Warrants The following table shows a summary of common stock warrants through December 31, 2020: Weighted Weighted Average Number of Average Contractual Warrants Exercise Price Term in Years Outstanding at December 31, 2019 5,250,000 $ 0.014000 2.81 Granted 2,117,500 $ 0.050720 3.30 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2020 7,367,500 $ 0.050720 2.05 Exercisable at December 31, 2020 7,367,500 $ 0.050720 2.05 As of December 31, 2020, vested outstanding warrants had $408 thousand intrinsic value as the exercise price is greater than the estimated fair value of the underlying common stock.

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2020
Note Payable
Note Payable	13. PPP Loan On April 22, 2020, the Company, entered into a promissory note (the “Promissory Note”) with PNC Bank, N.A. (the “Bank”), which provides for a loan in the amount of $147,300 (the “PPP Loan”) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The PPP Loan has a two-year term and bears interest at a rate of 1.0% per annum. Monthly principal and interest payments are deferred for six months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. The Promissory Note contains events of default and other provisions customary for a loan of this type. The Paycheck Protection Program provides that the PPP Loan may be partially or wholly forgiven if the funds are used for certain qualifying expenses as described in the CARES Act. The Company used the proceeds from the PPP Loan for qualifying expenses and to apply for forgiveness of the PPP Loan in accordance with the terms of the CARES Act. However, the Company cannot completely assure at this time that such forgiveness of the PPP Loan will occur. Economic Injury Disaster Loan On May 28, 2020, the Company entered into the standard loan documents required for securing a loan (the “EIDL Loan”) from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan is up to $260,500, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning May 28, 2021 (twelve months from the date of the SBA Note in the amount of $1,270. The balance of principal and interest is payable thirty years from the date of the SBA Note. In connection therewith, the Company received an $8,000 advance, which does not have to be repaid.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Convertible Notes Payable
Convertible Notes Payable	14. On December 24, 2020, the Company entered into two Securities Purchase Agreement, dated December 24, 2020 (the “Purchase Agreement”) pursuant to which the Company issued the following (i) $100,000 6% Secured Convertible Promissory Note which was convertible into shares of the Company’s common stock at a price per share of $0.08 and (ii) Common Stock purchase warrants to purchase up to 312,500 shares of common stock with an exercise price of $0.08. The notes are secured by all of the assets and equipment owned by the Company. The notes are due on or before June 24, 2021.

Warrant Liability

Warrant Liability	12 Months Ended
	Dec. 31, 2020
Warrant Liability
Warrant Liability	15. On December 24, 2020, March 18, 2020, September 10, 2019 and November 6, 2019, the Company issued 255,000, 1,550,000, 1,250,000 and 4,000,000 warrants, respectively, as equity issuance consideration, in connection with a private placement of the Company’s common stock. The warrants entitle the holder to purchase one share of our common stock at an exercise price equal to $0.014 to $0.080 per share at any time on or after their issuance date and on or prior to the close of business 3 years after the issuance date (the “Termination Date”). The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants required classification as a liability pursuant to ASC 815. In accordance with the accounting guidance, the outstanding warrants are recognized as a warrant liability on the balance sheet and are measured at their inception date fair value and subsequently re-measured at each reporting period with changes being recorded as a component of other income in the statement of operations. The fair value of the warrant liabilities was measured using a Black-Scholes model. Significant inputs into the model at the inception are as follows: Issuance date (1) Issuance date (2) Issuance date (3) Issuance date (4) Black-Scholes Assumptions December 24, 2020 March 18, 2020 September 10, 2019 November 6, 2019 Exercise Price (1)(2)(3)(4) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Warrant Expiration Date (1)(2)(3)(4) December 24, 2020 March 18, 2023 September 10, 2022 November 6, 2022 Stock Price (5) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Interest Rate (annual) (6) 0.17 % 0.66 % 1.61 % 1.60 % Volatility (annual) (7) 172.54 % 137.41 % 139.84 % 138.48 % Time to Maturity (Years) 3.0 3. 0 3.0 3. 0 Calculated fair value per share $ 0.0307299 $ 0.01091 $ 0.1095 Future Estimated Quarterly Dividend per share (8) — $ — $ — $ — Significant inputs into the model at the reporting period measurement dates are as follows: Issuance Issuance Date date Issuance date Issuance date December 31, December 31, Black-Scholes Assumptions December 31, 2020 December 31, 2020 2020 2020 Exercise Price (1)(2)(3)(4) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Warrant Expiration Date (1)(2)(3)(4) December 24, 2020 March 18, 2023 September 10, 2022 November 6, 2022 Stock Price (5) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Interest Rate (annual) (6) 0.17 % 0.13 % 0.13 % 1.13 % Volatility (annual) (7) 172.38 % 172.38 % 172.38 % 172.38 % Time to Maturity (Years) 2.98 2.21 1.85 1.69 Calculated fair value per share 0.0692188 $ 0.0307299 $ 0.01091 $ 0.1095 Future Estimated Quarterly Dividend per share (8) $ — $ — $ — Year ending Year ending Black-Scholes Assumptions December 31, 2019 December 31, 2019 Exercise Price (1)(2)(3)(4) $ 0.014 $ 0.014 Warrant Expiration Date (1)(2)(3)(4) September 10, 2022 November 6, 2022 Stock Price (5) $ 0.014 $ 0.014 Interest Rate (annual) (6) 1.62 % 1.62 % Volatility (annual) (7) 137.47 % 137.47 % Time to Maturity (Years) 2.70 2.85 Calculated fair value per share $ 0.01045 $ 0.01064 Future Estimated Quarterly Dividend per share (8) $ — $ — (1) Based on the terms provided in the warrant agreement related to the issuance of common stock of on December 24 th , 2020 (2) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 18 th , 2020 (3) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 10 th , 2019 (4) Based on the terms provided in the warrant agreement related to the issuance of common stock of on November 6 th , 2019 (5) Based on the observable transaction value of common stock of per the most recent stock issuance financing agreements. (6) Interest rate for U.S. Treasury Bonds, as of the issuance dates and each presented period ending date, as published by the U.S. Federal Reserve. (7) Based on the historical daily volatility of Guideline Public Companies and each presented period ending date. (8) Current estimated dividend payments beyond initial four quarters. At a future date, the company will review the working capital needs and make a final determination of any future dividend payments. The warrants outstanding and fair values at each of the respective valuation dates are summarized below: Warrants Fair Value Warrant Liability Outstanding per Share Fair Value Fair Value at initial measurement date of 9/10/2019 1,250,000 $ 0.01091 $ 14 Fair Value at initial measurement date of 11/6/2019 4,000,000 $ 0.01085 $ 43 Fair Value as of period ending 12/31/2019 5,250,000 $ 56 Fair Value at initial measurement dates of 2020 1,805,000 $ 0.03671 $ 65 Change in fair value of warrant liability 2 Fair Value as of period ending 12/31/2020 7,055,000 $ 123 The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about of future activities and the Company’s stock prices and historical volatility of Guideline Public Companies as inputs. As of December 31, 2020, none of the warrants have been exercised.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions
Related Party Transactions	16. Convertible Promissory Note On December 24, 2020, the Company issued a Secured Convertible Promissory Notes in the amount of $100,000 to Mr. Stein, a member of the board of directors and an entity affiliated to Mr. Stein, N&F Trust 774 (See Note 14). Sports Defense Acquisition On May 29, 2020, the Company entered into a Membership Interest Purchase Agreement whereby the Company purchased all of the outstanding equity securities of Sport Defense LLC. , Adam Levy, the Company’s Chief Executive Officer and Chief Financial Officer, and Nachum Stein, a member of the Company’s Board of Directors (the “Board”), were each members of Sport Defense and part of the Sellers. Mr. Levy received 1,546,875 of the shares and Mr. Stein received 3,187,500 of the shares (See Note 4). Advances Dr. Jerome Zeldis, a member of the Company Board, has an outstanding balance due of $30,000 for services as of December 31, 2020. The Spin-off While the Company was owned by Adynxx, the Company was included within the consolidation process of Adynxx. The Company’s operating losses of $612 million in the year ending December 31, 2019 were included within Adynxx’s financial results. All significant intercompany transactions and related party transactions between the Company and Adynxx have been included in these financial statements, as these statements were prepared on a “carve-out basis” prior to the Spin-Off. For the year ended December 31, 2019, cash flows from our Adynxx was $1.35 million, all of which were cash advances. The total net effect of the settlement of these transactions detailed above is reflected in the Statements of Cash Flows as a financing activity and in the Balance Sheets as parent’s net investment of $1,345 as of December 31, 2019.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Taxes
Income Taxes	17. The Company has established a full valuation allowance for its deferred tax assets based on management’s belief that it is not more likely than not that the related deferred tax assets will be realized. For the years ended December 31, 2020 and 2019, there was no income tax expense or benefit. At December 31, 2020 and December 31, 2019, the Company had no recorded tax liabilities for uncertain tax positions. The Company has not yet filed any federal or state income tax returns for its stand-alone operations for years that are open for examination. The Company does not expect any significant changes to the estimate amount of liabilities associated with uncertain tax positions in the next 12 months. Pursuant to the Spin-off, the Company and Alliqua BioMedical, Inc. entered into a Tax Matters Agreement to provide for the payment of tax liabilities and entitlement of refunds; allocation of the responsibility for, and cooperation in, filing of tax returns; and other matters relating to taxes for the pre- and post-Spin-off periods. Prior to the consummation of the Spin-Off, NexGel’s operating results were included in Adynxx consolidated U.S. federal and state income tax returns. For the purposes of the Company’s Consolidated and Combined Financial Statements for periods prior to the Separation, income tax expense and deferred tax balances have been recorded as if the Company filed tax returns on a standalone basis separate from Adynxx. The Separate Return Method applies the accounting guidance for income taxes to the standalone financial statements as if the Company was a separate taxpayer and a standalone enterprise prior to the separation from Adynxx. The income tax (benefit) provision consists of the following: For The Years Ended December 31, 2020 2019 Federal: Current $ — $ — Deferred — — State and local: Current — — Deferred — — Income tax provision $ — $ — Company has established a full valuation allowance for its deferred tax assets based on management’s belief that it is not more likely than not that the related deferred tax assets will be realized. For the years ended December 31, 2020 and 2019, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows: For The Years Ended December 31, 2020 2019 U.S. federal statutory rate 21.0 % 21.0 % State tax rate, net of federal benefit % % Permanent differences  Non-deductible expenses (1.27) % (0.7) % State tax change 0.0 % 0.0 % Change in valuation allowance (25.03) % (25.6) % Income tax provision 0.0 % 0.0 % For the years ended December 31, 2020 and 2019, differences between the expected tax expense based on the federal statutory rate and the actual tax expense is primarily attributable to losses for which no benefit is recognized. As of December 31, 2020 and 2019, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: As of December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 2,494 $ 2,110 Intangible Assets — — Other 3 2 Total deferred tax assets 2,497 2,112 Valuation allowance (2,382) (2,072) Deferred tax assets, net of valuation allowance $ 115 $ 40 Deferred tax liabilities: Property and equipment, net (115) (40) Total deferred tax liabilities (115) (40) Net deferred tax liabilities $ — $ — The deferred tax assets associated with net operating losses included in the table above reflect proforma net operating losses as if the Company were a separate taxpayer during the periods presented. As of December 31, 2020 and 2019, reported approximately $10.0 million and $8.0 million of federal NOL carryovers, respectively, which begin to expire in 2029 and through 2036. Similarly, the subsidiary’s Pennsylvania state returns reported state NOL carryovers of approximately $10 million and $7.9 million, as of December 31, 2020 and 2019, respectively. However, these loss carryforwards on a separate company basis may be subject to limitations on the amounts that may be utilized pursuant to Internal Revenue Code section 382 and applicable state law. Section 382 imposes significant limitations on the utilization of net operating losses after certain changes of corporate ownership. The Company will need to determine the amount of loss carryforwards that may be utilized in the future as necessary. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2020 and 2019 because management has determined that it is more likely than not that these deferred tax assets will not be realized. The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2020 and 2019, the Company does not have any significant uncertain tax positions .

Concentration of Risk

Concentration of Risk	12 Months Ended
	Dec. 31, 2020
Concentration of Risk
Concentration of Risk	18. The Company’s revenues are concentrated in a small group of customers with some individually having more than 10% of total revenues. Revenues from three customers that exceeded 10% of total revenues for the year ended December 31, 2020 were 45%, 22%, and 11%. The accounts receivable from the top three customers were 57%, 0%, and 0% as well as 12% from one other customer of the total accounts receivable as of December 31, 2020. Revenues from four customers that exceeded 10% of total revenues for the year ended December 31, 2019 were 38%, 17%, 13% and 10%. Accounts receivable from these same four customers were 0%, 13%, 0% and 34% as well as 43% from three other customers of the total accounts receivable as of December 31, 2019. The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash. Cash balances are maintained principally at major U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. From time to time, cash balances may exceed the FDIC insurance limit. The Company has not experienced any credit losses associated with its cash balances in the past.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events
Subsequent Events	19. Auctus Financing On March 11, 2021 (the “Issuance Date”), the Company entered into a securities purchase agreement (the “Auctus Purchase Agreement”) with Auctus Fund, LLC, a Delaware limited liability company (“Auctus”), pursuant to which the Company issued to Auctus a senior secured convertible promissory note in the principal amount of $1,500,000 (the “Auctus Note”). The net proceeds received by the Company were $1,337,000 (after deducting fees and expenses related to the transaction, including a payment to Alere (as defined and discussed below). The Company intends to use the net proceeds for working capital and general corporate purposes. The Auctus Note has a maturity date of one year from the Issuance Date. The Auctus Note bears interest at a rate of 12% per annum, which is also payable on maturity, with the understanding that the first 12 months of interest (equal to $180,000) is guaranteed and deemed to be earned in full as of the Issuance Date. In the event the Company fails to pay any amount when due under the Auctus Note, the interest rate will increase to the greater of 16% or the maximum amount permitted by law. The Auctus Note may be prepaid during the first 180 calendar days from the Issuance Date subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. The Auctus Note may not be paid in whole or in part after 180 calendar days from the Issuance Date. Auctus may convert any amount due under the Auctus Note at any time, and from time to time, into shares of the Company’s common stock at a conversion price of $0.10 per share; provided, however, that Auctus may not convert any portion of the Auctus Note that would cause it to beneficially own in excess of 4.99% of the Company’s common stock. The conversion price and number of shares of the Company’s common stock issuable upon conversion of the Auctus Note will be subject to adjustment from time to time for any subdivision or consolidation of shares and other standard dilutive events. The Auctus Note contains a number of events of default, including but not limited to the following: (i) the Company’s failure to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE American within 120 days of the Issuance Date (the “Trading Date”) and (ii) the Company’s failure to file a registration statement covering the Auctus’ resale at prevailing market prices (and not fixed prices) of all of the common stock underlying the Auctus Note and the Auctus Warrants (as defined below) within 30 calendar days following the Issuance Date, (ii) cause the registration statement to become effective within 150 calendar days following the Issuance Date. An event of default is subject to a confession of judgement against the Company in the favor of Auctus. Additionally, the Auctus Note is secured by all of the assets of the Company pursuant to a security agreement that was entered into in connection with the issuance of the Auctus Note (the “Security Agreement”); provided, however, the Security Agreement will be automatically terminated as of the Trading Date assuming no event of default then exists. In connection with the issuance of the Auctus Note, Auctus was also issued two five-year warrants as follows: the first warrant was to purchase up to an aggregate of 6,000,000 shares of the Company’s common stock at an exercise price of $0.125 per share (the “First Auctus Warrant") and the second warrant was to purchase up to an aggregate of 5,000,000 shares of the Company's common stock at an exercise price of $0.15 per share (the "Second Auctus Warrant"). The First Auctus Warrant and the Second Auctus Warrant are referred to herein as the “Auctus Warrants” and the shares of the Company’s common stock underlying the Auctus Warrants are referred to as the “Auctus Warrant Shares”. Auctus may not exercise the Auctus Warrants with respect to any number of Auctus Warrant Shares that would cause it to beneficially own in excess of 4.99% of the Company’s common stock. The Auctus Warrants may be exercised for cash, or, if the “market price” of the Company’s common stock is greater than the Auctus Warrant’s exercise price, and there is not an effective registration statement covering the Auctus Warrant Shares, the Auctus Warrants may be exercised on a cashless basis. The number of shares of common stock to be deliverable upon exercise of the Auctus Warrants is subject to adjustment for subdivision or consolidation of shares and other standard dilutive events, or in the event the Company effects a reorganization, reclassification, merger, consolidation, disposition of assets, or other fundamental transaction. Pursuant to the Auctus Purchase Agreement, the Company granted Auctus piggyback registration rights with respect to the shares underlying the Auctus Note and the Auctus Warrant. In addition, the Company agreed that, while any amount remains unpaid under the Auctus Note, it would not sell securities on more favorable terms than those provided to Auctus, without adjusting Auctus’ terms accordingly. Further, among other things, the Company agreed that, while any amount remains unpaid under the Auctus Note, it would not enter into any variable rate transactions. Further and in connection with the issuance of the Auctus Note, the Company entered into a registration rights agreement with Auctus (the “Registration Rights Agreement”) whereby it the Company agreed to (i) file with the Securities and Exchange Commission a registration statement covering resale by Auctus at prevailing market prices (and not fixed prices) of all of the common stock underlying the Auctus Note and the Auctus Warrants within 30 calendar days following the Issuance Date, (ii) cause the registration statement to become effective within 150 calendar days following the Issuance Date. Alere Financial, A Division of Cova Capital Partners, LLC (“Alere”), served as the placement agent for the Auctus Note and received a total cash fee equal to $120,000 (or 8% of the principal amount of the Auctus Note). Mr. Levy, the Company’s Chief Executive Officer and Chief Financial Officer, is affiliated with Alere but has waived any portion of such fee received by Alere to which he is entitled as an affiliate of Alere. Private Placement From January 1, 2021 through March, 2021, the Company entered into Securities Purchase Agreements with certain accredited investors whereby we sold 3,562,500 shares of our common stock at a price per share equal to $0.08 for an aggregate purchase price of $285,000. Equity Grants On March 8, 2021, the Company granted a restricted stock award of 1,383,333 shares of the Company’s common stock to the Adam Levy for his service as our Chief Executive Officer and Chief Financial Officer from October 1, 2020 through September 30, 2021. This equity award fully vested as of the date of grant. On March 8, 2021, the Company granted Dr. Jerome Zeldis, a member of the Company Board, an option to purchase up to 666,667 shares of the Company’s common stock at a per share exercise price of $0.06 under the Company’s 2019 Long-Term Incentive Plan. This option award fully vested as of the date of grant. Board of Director Appointment On March 8, 2021, the Company appointed Steven Glassman to the Board of Directors to serve for a term expiring at the next annual meeting of stockholders or until his successor is duly elected and qualified. On March 8, 2021 and in consideration for his appointment to the board of directors, the Company granted Mr. Glassman an option to purchase up to 500,000 shares of common stock at a per share exercise price of $0.08 under the Company’s 2019 Long-Term Incentive Plan. This option award fully vested as of the date of grant. Paycheck Protection Program – Phase II On March 4, 2021, the Company received a second PPP Loan in the amount of $127 thousand under Phase II of the Paycheck Protection Program which commenced on January 13, 2021 and allowed certain businesses that received an initial PPP Loan to seek a second draw PPP Loan.

Significant Accounting Polici_2

Significant Accounting Policies and Estimates (Policies)	12 Months Ended
	Dec. 31, 2020
Significant Accounting Policies and Estimates
Use of estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions include allowance for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.
Cash	Cash Cash include cash on hand and highly liquid investments having an original maturity of three months or less.
Accounts receivable, net	Accounts receivable, net Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $1 thousand as of December 31, 2020 and $2 thousand as of December 31, 2019.
Inventory	Inventory Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence or shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value. The balance is made up of raw materials, work-in-progress, and finished goods of $190 thousand, $22 thousand and $21 thousand on December 31, 2020, respectively, and was $113 thousand of raw material on December 31, 2019. As a contract manufacturer, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process. There were no work in progress or finished goods inventories as of December 31, 2019.
Property and equipment, net	Property and equipment, net Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets ’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred. Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life. The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the period of disposal and the resulting gains and losses are included in the results of operations during the same period.
Impairment of Long-lived assets	Impairment of Long-Lived Assets We review the recoverability of our long-lived assets, including equipment and right-of-use assets, when events or changes in circumstances occur that indicate that the carrying value of the asset, or asset group, may not be recoverable. Events or circumstances that might cause management to perform impairment testing include, but are not limited to, significant underperformance relative to historical or projected future operating results of the asset or asset group, significant changes in the manner or use of assets or the strategy for our overall business; and significant negative industry or economic trends. If indicators of potential impairment are present, management performs a recoverability test and, if necessary, records an impairment loss. If the total estimated future undiscounted cash flows to be generated from the use and ultimate disposition of an asset or asset group is less than its carrying value, an impairment loss is recorded in the Company’s results of operations, measured as the amount required to reduce the carrying value to fair value. Fair value is determined in accordance with the best available information per the hierarchy described under Fair Value Measurements below. For example, the Company would first seek to identify quoted prices or other observable market data. If observable data is not available, Management would apply the best available information under the circumstances to a technique such as a discounted cash flow model to estimate fair value. Impairment analysis involves estimates and the use of assumptions due to the inherently judgmental nature of forecasting long-term estimated inflows and outflows resulting from the use and ultimate disposition of an asset, and determining the ultimate useful lives of assets. Actual results may differ from these estimates using different assumptions, which could materially impact the results of an impairment assessment.
Prepaid expenses and other current assets	Prepaid expenses and other current assets Prepaid expenses and other current assets is recorded at historical cost and is primarily made up of $16 thousand and $18 thousand of prepaid insurance, and $9 thousand and $17 thousand general prepaid expenses and other current assets in the years ended December 31, 2020 and 2019 respectively.
Other Assets	Other Assets Other Assets is recorded at historical costs, and as of December 31, 2020, the balance is entirely made up of spare parts for manufacturing equipment. Other assets are stated at cost and are not subject to depreciation, until such time that they are placed into service and the part that is being replaced is disposed.
Fair value measurements	Fair value measurements The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: Level 1 —Quoted prices for identical assets or liabilities in active markets. Level 2 —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable. The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.
Warrant Liability	Warrant Liability Warrants to purchase common stock were issued in connection with equity financing raises, which occurred on December 24, 2020, March 18, 2020, September 10, 2019 and November 6, 2019. The fair values of the warrants are estimated as of the date of issuance and again at each period end using a Black-Scholes option valuation model. At issuance, the fair value of the warrant is recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.
Revenue recognition	Revenue recognition On January 1, 2018, the Company adopted Accounting Standards Codification ( “ ASC ” ) Topic 606, Revenue from Contracts with Customers ( “ ASC 606 ” ). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing accounting principles generally accepted in the United States of America (“U.S. GAAP”) including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required. The Company recognizes revenue predominately from one type of revenue, contract manufacturing. Revenue from contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. The Company’s customers consist of other life sciences companies and revenues are concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial. As of December 31, 2020 and 2019, the Company did not have any contract assets or contract liabilities from contracts with customers. As of December 31, 2020 and December 31, 2019, there were no remaining performance obligations that the Company had not satisfied.
Share-based compensation	Share-based compensation On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan (the "2019 Plan"). The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights ("SARs"), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initial reserved a total of 2,000,000 shares of the Company's common stock for awards under the 2019 Plan. Effective as of May 26, 2020, the Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan from 2,000,000 shares of common stock to 17,000,000 shares of common stock all of which may be delivered pursuant to incentive stock options. Subject to adjustments pursuant to the 2019 Plan, the maximum number of shares of common stock with respect to which stock options or SARs may be granted to an executive officer during any calendar year is 500,000 shares of common stock. The Company’s 2019 Long-Term Incentive Plan provides certain employees, contractors and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur. In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018‑07, Compensation - Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting . These amendments expand the scope of Topic 718, Compensation - Stock Compensation , to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This new standard is effective for the Company on January 1, 2020. The Company early adopted this new standard in the third quarter of 2019 and it did not have material impact to its condensed financial statements.
Income taxes	Income taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.
Segment reporting	Segment reporting The Company operates in one business segment as a contract manufacturer of aqueous polymer hydrogels. As a result, the Company’s operations are a single reportable segment, which is consistent with the Company’s internal management reporting.
Comprehensive loss	Comprehensive loss Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all periods presented,
Recently Adopted and Issued Accounting Standards	Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (the "FASB”) established ASC Topic 842, Leases , by issuing Accounting Standards Update (“ASU”) No. 2016‑02, which requires lessees to recognize operating leases on the balance sheet and disclose key information about leasing arrangements. ASC Topic 842 was subsequently amended by ASU No. 2018‑01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018‑10, Codification Improvements to Topic 842, Leases; and ASU No. 2018‑11, Targeted Improvements . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases. Leases will be classified as either finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. Lessor accounting under the new standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the new standard on leases on January 1, 2019. The Company currently recognizes an operating lease right-of-use asset and a corresponding lease liability on its condensed balance sheet. The Company also applies the following accounting policies related to this standard: · The Company does not recognize ROU assets and liabilities for leases with a term of 12 months or less; and · The Company does not separate lease and non-lease components in the Company ’ s lease contracts. Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Financial Instruments— Credit Losses In June 2016, the FASB issued ASU No. 2016‑13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In November 2019, the FASB issued ASU No. 2019‑10 Financial Instruments — Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842). The update allows the extension of the initial effective date for entities which have not yet adopted ASU No. 2016‑02. The standard is effective for annual reporting periods beginning after December 15, 2022, with early adoption permitted for annual reporting periods beginning after December 15, 2018. Entities will apply the standard’s provisions by recording a cumulative effect adjustment to retained earnings. The Company has not yet adopted ASU 2016‑13 and currently assessing the impact of this new standard on its financial statements. Collaborative Arrangements In November 2018, the FASB issued ASU 2018‑18, Collaborative Arrangements (Topic 808). This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers (“ASU 2018‑18”) . The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018‑18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s financial statements as the Company does not have any collaborative agreements. However, there is a potential for the Company to enter into collaborative agreements in the future, as it expands into consumer markets. Fair Value Measurement—Disclosure Framework In August 2018, the FASB issued ASU No. 2018‑13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018‑13”), which amends ASC Topic 820, Fair Value Measurements. ASU 2018‑13 modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The effective date is the first quarter of fiscal year 2021, with early adoption permitted for the removed disclosures and delayed adoption permitted until fiscal year 2021 for the new disclosures. The removed and modified disclosures will be adopted on a retrospective basis and the new disclosures will be adopted on a prospective basis. The Company has not yet adopted ASU 2018‑13 and currently assessing the impact of this new standard on its financial statements.

Description of Business, the _2

Description of Business, the Spin-off and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2020
Description of Business, the Spin-off and Basis of Presentation
Schedule of net liabilities assumed pursuant to Spin-Off and in exchange	Pursuant to the Spin-Off and in exchange for the 5,005,211 shares of common stock, NexGel assumed the following net liabilities from Parent as of June 21, 2019 ($ in thousands): Assets: Cash $ 186 Accounts receivable, net 72 Inventory 140 Prepaid expenses and other current assets 101 Property and equipment, net 155 Operating lease - right of use asset 976 Other assets 178 Total assets 1,808 Liabilities: Accounts payable (496) Accrued expenses and other current liabilities (395) Operating lease liability (976) Total liabilities (1,867) Net liabilities assumed in Spin-Off on June 21, 2019 $ (59)

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2020
Acquisition
Schedule of preliminary analysis for the Sports Defense acquisition	Provisional Purchase Consideration at preliminary fair value: Purchase price $ 375 Amount of consideration $ 375 Assets acquired and liabilities assumed at preliminary fair value Inventories 21 Product/Technology related intangibles 31 Marketing related intangibles 8 Customer related intangibles 17 Accounts payable and accrued expenses (13) Other liabilities — Net tangible assets acquired $ 64 Total net assets acquired $ 64 Consideration paid 375 Preliminary goodwill $ 311
Schedule of unaudited pro-forma results of operations	For the Year Ended December 31, 2020 2019 Revenues, net $ 691 $ 760 Net loss allocable to common shareholders $ (2,254) $ (1,963) Net loss per share $ (0.03) $ (0.09) Weighted average number of shares outstanding 86,707,552 22,945,585

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases
Schedule of future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases	The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2020 ($ in thousands): Operating Lease Maturity of Lease Liability Liability 2021 $ 207 2022 207 2023 207 2024 207 2025 207 Thereafter 18 Total undiscounted operating lease payments $ 1,053 Less: Imputed interest (248) Present value of operating lease liability $ 805 Weighted average remaining lease term 5.0 years Weighted average discount rate %
Schedule of Summary of supplemental cash flows information related to leases	Supplemental cash flows information related to leases was as follows ($ in thousands): December 31, 2019 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating lease $ 207 Right-of-use asset obtained in exchange for lease obligation: Operating lease $ 805

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory
Schedule of inventories	Inventory consists of the following ($ in thousands): December 31, December 31, 2020 2019 Raw materials $ 190 $ 113 Work-in-progress 22 — Finished goods 21 — 233 113 Less: Inventory reserve for excess and slow moving inventory — — Total $ 233 $ 113

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property and Equipment, Net
Schedule of property and equipment, net	Useful Life December 31, December 31, (Years) 2020 2019 Machinery and equipment 3 - 10 $ 2,894 $ 2,893 Office furniture and equipment 3 - 10 49 49 Leasehold improvements 6 228 228 Construction in progress N/A 461 150 3,632 3,320 Less: accumulated depreciation and amortization (3,079) (3,038) Property and equipment, net $ 553 $ 282

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Intangible Assets
Schedule of identifiable intangible assets	December 31, 2020 Product/Technology Related Identifiable intangible assets, gross $ 31 Accumulated amortization (6) Product/Technology Related identifiable intangible assets, net 25 Marketing Related Customer related intangible asset, gross 17 Tradename related intangible asset, gross 7 Accumulated amortization (2) Marketing related identifiable intangible assets, net 22 Total Identifiable intangible assets, net $ 47
Schedule of estimated annual amortization expense	As of December 31, 2020, the estimated annual amortization expense for each of the next five fiscal years is as follows: 2021 $ 14 2022 14 2023 8 2024 3 2025 2 Thereafter 6 Total $ 47

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consist of the following ($ in thousands): December 31, December 31, 2020 2019 Salaries, benefits and incentive compensation $ 43 $ 14 Professional fees — — Other 47 14 Total accrued expenses and other current liabilities $ 90 $ 28

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Common Stock
Summary of reserved of common stock for issuance	At December 31, 2020, the Company has reserved common stock for issuance in relation to the following: Share-based compensation plan 17,000,000 Warrants to purchase common stock 9,172,500

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Compensation
Schedule of information about 2019 plan	The following table contains information about the 2020 Plan as of December 31, 2020: Awards Awards Reserved for Available for Issuance Awards Issued Grant 2019 Plan 17,000,000 13,705,949 3,294,051
Schedule of incentive stock option activity	The following table summarizes the Company’s incentive stock option activity and related information for the period ended December 31, 2020: Weighted Weighted Average Number of Average Contractual Options Exercise Price Term in Years Outstanding at June 21, 2019 — — — Granted 1,000,000 $ 0.053525 10.0 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2019 1,000,000 $ 0.053525 9.6 Granted 12,705,949 $ 0.0291 10.0 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2020 13,705,949 $ 0.027736 Exercisable at December 31, 2020 12,455,949 $ 0.024498
Schedule of assumptions used in share-based compensation	The following assumptions were used to calculate share-based compensation expense for year ended December 31, 2020: Volatility 136.81% - 171.47 % Risk-free interest rate 0.29% - 1.39 % Dividend yield 0.0 % Expected term 5.0 - 6.0 years
Schedule of restricted stock awards activity	Weighted Average Number of Grant Date Units Fair Value Granted 7,311,904 $ 0.023 Exercised and converted to common shares (5,928,571) 0.014 Forfeited — — Outstanding at December 31, 2020 1,383,333 $ 0.060 Exercisable at December 31,2020 345,833 $ 0.060
Summary of common stock warrants	Weighted Weighted Average Number of Average Contractual Warrants Exercise Price Term in Years Outstanding at December 31, 2019 5,250,000 $ 0.014000 2.81 Granted 2,117,500 $ 0.050720 3.30 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2020 7,367,500 $ 0.050720 2.05 Exercisable at December 31, 2020 7,367,500 $ 0.050720 2.05

Warrant Liability (Tables)

Warrant Liability (Tables)	12 Months Ended
	Dec. 31, 2020
Warrant Liability
Schedule of warrant liability	Issuance date (1) Issuance date (2) Issuance date (3) Issuance date (4) Black-Scholes Assumptions December 24, 2020 March 18, 2020 September 10, 2019 November 6, 2019 Exercise Price (1)(2)(3)(4) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Warrant Expiration Date (1)(2)(3)(4) December 24, 2020 March 18, 2023 September 10, 2022 November 6, 2022 Stock Price (5) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Interest Rate (annual) (6) 0.17 % 0.66 % 1.61 % 1.60 % Volatility (annual) (7) 172.54 % 137.41 % 139.84 % 138.48 % Time to Maturity (Years) 3.0 3. 0 3.0 3. 0 Calculated fair value per share $ 0.0307299 $ 0.01091 $ 0.1095 Future Estimated Quarterly Dividend per share (8) — $ — $ — $ — Significant inputs into the model at the reporting period measurement dates are as follows: Issuance Issuance Date date Issuance date Issuance date December 31, December 31, Black-Scholes Assumptions December 31, 2020 December 31, 2020 2020 2020 Exercise Price (1)(2)(3)(4) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Warrant Expiration Date (1)(2)(3)(4) December 24, 2020 March 18, 2023 September 10, 2022 November 6, 2022 Stock Price (5) $ 0.08 $ 0.04 $ 0.014 $ 0.014 Interest Rate (annual) (6) 0.17 % 0.13 % 0.13 % 1.13 % Volatility (annual) (7) 172.38 % 172.38 % 172.38 % 172.38 % Time to Maturity (Years) 2.98 2.21 1.85 1.69 Calculated fair value per share 0.0692188 $ 0.0307299 $ 0.01091 $ 0.1095 Future Estimated Quarterly Dividend per share (8) $ — $ — $ — Year ending Year ending Black-Scholes Assumptions December 31, 2019 December 31, 2019 Exercise Price (1)(2)(3)(4) $ 0.014 $ 0.014 Warrant Expiration Date (1)(2)(3)(4) September 10, 2022 November 6, 2022 Stock Price (5) $ 0.014 $ 0.014 Interest Rate (annual) (6) 1.62 % 1.62 % Volatility (annual) (7) 137.47 % 137.47 % Time to Maturity (Years) 2.70 2.85 Calculated fair value per share $ 0.01045 $ 0.01064 Future Estimated Quarterly Dividend per share (8) $ — $ — (1) Based on the terms provided in the warrant agreement related to the issuance of common stock of on December 24 th , 2020 (2) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 18 th , 2020 (3) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 10 th , 2019 (4) Based on the terms provided in the warrant agreement related to the issuance of common stock of on November 6 th , 2019 (5) Based on the observable transaction value of common stock of per the most recent stock issuance financing agreements. (6) Interest rate for U.S. Treasury Bonds, as of the issuance dates and each presented period ending date, as published by the U.S. Federal Reserve. (7) Based on the historical daily volatility of Guideline Public Companies and each presented period ending date. (8) Current estimated dividend payments beyond initial four quarters. At a future date, the company will review the working capital needs and make a final determination of any future dividend payments. The warrants outstanding and fair values at each of the respective valuation dates are summarized below: Warrants Fair Value Warrant Liability Outstanding per Share Fair Value Fair Value at initial measurement date of 9/10/2019 1,250,000 $ 0.01091 $ 14 Fair Value at initial measurement date of 11/6/2019 4,000,000 $ 0.01085 $ 43 Fair Value as of period ending 12/31/2019 5,250,000 $ 56 Fair Value at initial measurement dates of 2020 1,805,000 $ 0.03671 $ 65 Change in fair value of warrant liability 2 Fair Value as of period ending 12/31/2020 7,055,000 $ 123

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Taxes
Schedule of income tax (benefit) provision	For The Years Ended December 31, 2020 2019 Federal: Current $ — $ — Deferred — — State and local: Current — — Deferred — — Income tax provision $ — $ —
Schedule of expected tax benefit based on the statutory rate reconciled	For The Years Ended December 31, 2020 2019 U.S. federal statutory rate 21.0 % 21.0 % State tax rate, net of federal benefit % % Permanent differences  Non-deductible expenses (1.27) % (0.7) % State tax change 0.0 % 0.0 % Change in valuation allowance (25.03) % (25.6) % Income tax provision 0.0 % 0.0 %
Schedule of deferred tax assets consisted of the effects of temporary differences	As of December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 2,494 $ 2,110 Intangible Assets — — Other 3 2 Total deferred tax assets 2,497 2,112 Valuation allowance (2,382) (2,072) Deferred tax assets, net of valuation allowance $ 115 $ 40 Deferred tax liabilities: Property and equipment, net (115) (40) Total deferred tax liabilities (115) (40) Net deferred tax liabilities $ — $ —

Description of Business, the _3

Description of Business, the Spin-off and Basis of Presentation (Details) - USD ($) $ in Thousands	Jun. 21, 2019	Apr. 22, 2019	Dec. 31, 2020	Dec. 31, 2019
Assets:
Cash			$ 32	$ 261
Accounts receivable, net			73	102
Inventory			233	113
Prepaid expenses and other current assets			25	37
Property and equipment, net			553	282
Operating lease - right of use asset			805	917
Other assets			178	178
Total assets			2,257	1,890
Liabilities:
Accounts payable			(658)	(510)
Accrued expenses and other current liabilities			(90)	(27)
Operating lease liability			(207)	(207)
Total liabilities			$ (2,186)	$ (1,510)
The Spin-Off
Description of Business, the Spin-off and Basis of Presentation
Number of shares received by holder of each common stock		1
Shares distributed	5,005,211	5,005,211
Assets:
Cash	$ 186
Accounts receivable, net	72
Inventory	140
Prepaid expenses and other current assets	101
Property and equipment, net	155
Operating lease - right of use asset	976
Other assets	178
Total assets	1,808
Liabilities:
Accounts payable	(496)
Accrued expenses and other current liabilities	(395)
Operating lease liability	(976)
Total liabilities	(1,867)
Net liabilities assumed in Spin-Off on June 21, 2019	$ (59)

Going Concern (Details)

Going Concern (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Going Concern
Cash	$ 32
Net loss	(2,264)	$ (1,923)
Net cash used in operating activities	(1,801)	$ (1,814)
Working capital deficit	$ 970

Going Concern - Share Purchase

Going Concern - Share Purchase Agreement (Details) - USD ($)	Mar. 11, 2021	Aug. 14, 2020	Mar. 20, 2020	Sep. 10, 2019	Mar. 31, 2021	Dec. 24, 2020	Mar. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Mar. 04, 2021	Feb. 29, 2020	Nov. 06, 2019
Subsidiary, Sale of Stock [Line Items]
Aggregate purchase price									$ 1,370,000	$ 673,000
Common stock, par value									$ 0.001	$ 0.001
Share Price												$ 0.014
Issuance of common stock, net of issuance costs									$ 1,370,000	$ 730,000
Net proceeds from notes issuance									$ 100,000	$ 0
Auctus Note
Subsidiary, Sale of Stock [Line Items]
Net proceeds from notes issuance							$ 1,337,000
Private placement
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)		6,585,000	15,500,000	3,269,500		4,437,500
Aggregate purchase price		$ 395,100	$ 620,000			$ 355,000
Common stock, par value		$ 0.06		$ 0.001									$ 0.001
Subsequent Events | Paycheck Protection Program, Phase II
Subsidiary, Sale of Stock [Line Items]
Loan amount											$ 127,000
Subsequent Events | Auctus Note
Subsidiary, Sale of Stock [Line Items]
Aggregate purchase price	$ 0.10
Loan amount											$ 127,000
Principal amount of debt	1,500,000
Net proceeds from notes issuance	$ 1,337,000
Subsequent Events | Private placement
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)					3,562,500			3,562,500
Aggregate purchase price					$ 285,000			$ 285,000
Common stock, par value					$ 0.08			$ 0.08

Significant Accounting Polici_3

Significant Accounting Policies and Estimates (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	May 26, 2020	May 25, 2020	Aug. 28, 2019
Allowance for doubtful accounts	$ 1	$ 2
Raw materials	190	113
Work-in-progress	22	0
Finished goods	21	0
prepaid insurance	16	18
General prepaid expenses	9	17
Remaining performance obligations	0	0
Decreae in additional paid-in capital due to warrant issued	65
Proceeds from issuance of convertible promissory notes	$ 100	$ 0
2019 Plan
Common stock reserved for issuance	17,000,000		17,000,000	2,000,000	2,000,000
Number of shares available for grant	13,705,949
2019 Plan | Executive officer
Number of shares available for grant			500,000		500,000

Acquisition (Details)

Acquisition (Details) - USD ($)	May 29, 2020	Dec. 31, 2020	Dec. 31, 2019
Provisional Purchase Consideration at preliminary fair value:
Purchase price	$ 375
Common stock, par value		$ 0.001	$ 0.001
Sports Defense LLC
Provisional Purchase Consideration at preliminary fair value:
Purchase price	$ 375
Issuance of common stock for acquisition (in shares)	9,375,000
Share purchase price	$ 0.04
Net assets acquired	$ 375,000
Mr. Levy | Sports Defense LLC
Provisional Purchase Consideration at preliminary fair value:
Issuance of common stock for acquisition (in shares)	1,546,875
Board of Director
Provisional Purchase Consideration at preliminary fair value:
Issuance of common stock for acquisition (in shares)	3,187,500

Acquisition - Preliminary Analy

Acquisition - Preliminary Analysis (Details) - USD ($)	May 29, 2020	Dec. 31, 2020	Dec. 31, 2019
Provisional Purchase Consideration at preliminary fair value:
Purchase price	$ 375
Consideration paid	375
Assets acquired and liabilities assumed at preliminary fair value
Inventories	21
Accounts payable and accrued expenses	(13)
Net tangible assets acquired	64
Total net assets acquired	64
Consideration paid	375
Preliminary goodwill	311	$ 311,000	$ 0
Product/Technology Related
Assets acquired and liabilities assumed at preliminary fair value
Intangibles	31
Marketing-Related
Assets acquired and liabilities assumed at preliminary fair value
Intangibles	8
Customer Related
Assets acquired and liabilities assumed at preliminary fair value
Intangibles	17
Sports Defense LLC
Provisional Purchase Consideration at preliminary fair value:
Purchase price	375
Consideration paid	375
Assets acquired and liabilities assumed at preliminary fair value
Consideration paid	375
Sports Defense LLC | Product/Technology Related
Provisional Purchase Consideration at preliminary fair value:
Purchase price	375
Consideration paid	375
Assets acquired and liabilities assumed at preliminary fair value
Consideration paid	$ 375

Acquisition - Pro-forma Results

Acquisition - Pro-forma Results (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Acquisition
Revenues, net	$ 691	$ 760
Net loss allocable to common shareholders	$ (2,254)	$ (1,963)
Net loss per share	$ (0.03)	$ (0.09)
Weighted average number of shares outstanding	86,707,552	22,945,585

Leases - Future minimum lease p

Leases - Future minimum lease payments (Details) $ in Thousands	Dec. 31, 2020USD ($)
Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases
2021	$ 207
2022	207
2023	207
2024	207
2025	207
Thereafter	18
Total undiscounted operating lease payments	1,053
Less: Imputed interest	(248)
Present value of operating lease liability	$ 805
Weighted average remaining lease term	5 years
Weighted average discount rate	11.00%

Leases - Supplemental cash flow

Leases - Supplemental cash flows information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Leases
Operating cash flows from operating lease	$ 207
Operating lease	$ 805

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases
Operating Lease, Cost	$ 207	$ 207
Lease, Cost		$ 207

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory, net
Raw materials	$ 190	$ 113
Work-in-progress	22	0
Finished goods	21	0
Inventory, Gross	233	113
Total	$ 233	$ 113

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment	$ 3,632	$ 3,320
Less: accumulated depreciation and amortization	(3,079)	(3,038)
Property and equipment, net	553	282
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment	$ 2,894	2,893
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Property and equipment	$ 49	49
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful Life	6 years
Property and equipment	$ 228	228
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	$ 461	$ 150

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property and Equipment, Net
Depreciation expense	$ 42	$ 67

Intangible Assets - Breakdown o

Intangible Assets - Breakdown of Identifiable Intangible Assets (Details) $ in Thousands	Dec. 31, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Total	$ 47
Product/Technology Related
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	31
Accumulated amortization	(6)
Total	25
Marketing-Related
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	(2)
Total	22
Customer Related
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	17
Marketing Related - Tradename related intangible asset
Acquired Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	$ 7

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - Technology related and Customer related intangibles - Sports Defense LLC $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Intangibles	$ 55
Expected life	2 years 7 months 6 days
Amortization expense	$ 8

Intangible Assets - Future Amor

Intangible Assets - Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2020USD ($)
Intangible Assets
2021	$ 14
2022	14
2023	8
2024	3
2025	2
Thereafter	6
Total	$ 47

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued Expenses and Other Current Liabilities
Salaries, benefits and incentive compensation	$ 43	$ 14
Professional fees	0
Other	47	14
Total accrued expenses and other current liabilities	$ 90	$ 28

Common Stock - Additional Infor

Common Stock - Additional Information (Details)	Oct. 10, 2020$ / shares	Aug. 14, 2020USD ($)$ / sharesshares	Mar. 20, 2020USD ($)$ / sharesshares	Feb. 17, 2020USD ($)$ / sharesshares	Nov. 06, 2019USD ($)$ / sharesshares	Sep. 10, 2019USD ($)shareholder$ / sharesshares	Dec. 24, 2020USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	May 26, 2020shares	May 25, 2020shares	Feb. 10, 2020shares	Feb. 09, 2020shares	Sep. 10, 2018$ / shares
Class of Stock [Line Items]
Common stock, par value								$ 0.001	$ 0.001
Aggregate purchase price | $								$ 1,370,000	$ 673,000
Authorized shares of common stock | shares								3,000,000,000	3,000,000,000	3,000,000,000	100,000,000	3,000,000,000	100,000,000
Restricted stock award
Class of Stock [Line Items]
Exercise Price	$ 0.06
Restricted stock award | Mr. Levy
Class of Stock [Line Items]
Share issued upon vesting of restricted stock awards | shares				5,928,571
2019 Long-Term Incentive Plan | Board of Director
Class of Stock [Line Items]
Aggregate purchase price | $				$ 40,000
First grant | 2019 Long-Term Incentive Plan | Board of Director
Class of Stock [Line Items]
Granted | shares				2,857,141
Exercise Price				$ 0.014
Private placement
Class of Stock [Line Items]
Common stock, par value		$ 0.06			$ 0.001	$ 0.001
Issue price per share			$ 0.04			$ 0.053525	$ 0.08							$ 0.014
Issuance of common stock (in shares) | shares		6,585,000	15,500,000			3,269,500	4,437,500
Cash proceeds | $					$ 560,000	$ 175,000
Number of shareholders | shareholder						2
Additional shares issued on common stock | shares					39,999,998	9,230,500
Issuance costs | $					$ 56,000	$ 5,000
Aggregate purchase price | $		$ 395,100	$ 620,000				$ 355,000
Percentage of fee equal to gross proceeds and warrants			6.00%
Percentage of shares issuable to warrant holders based on the number of shares issued to investors			10.00%
Exercise price of warrants			$ 0.04
Minimum | Private placement
Class of Stock [Line Items]
Exercise price of warrants								$ 0.014
Maximum | Private placement
Class of Stock [Line Items]
Value of common stock offered on initial closing date | $						175,000
Value of common stock offered on subsequent closing date | $						$ 575,000
Exercise price of warrants								$ 0.080

Common Stock - Common stock res

Common Stock - Common stock reserved for issuance (Details)	12 Months Ended
	Dec. 31, 2020shares
Common Stock
Share-based compensation plan	17,000,000
Warrants to purchase common Stock	9,172,500

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - $ / shares	Jun. 21, 2019	Apr. 22, 2019	Dec. 31, 2020	Dec. 31, 2019
Net Loss Per Common Share
Common stock, par value			$ 0.001	$ 0.001
The Spin-Off
Net Loss Per Common Share
Shares distributed	5,005,211	5,005,211
Common stock, par value	$ 0.001

Share-based Compensation - 2019

Share-based Compensation - 2019 Plan (Details) - 2019 Plan - shares	12 Months Ended
	Dec. 31, 2020	May 26, 2020	May 25, 2020	Aug. 28, 2019
Share-based Compensation
Common stock reserved for issuance	17,000,000	17,000,000	2,000,000	2,000,000
Awards Issued	13,705,949
Awards Available for Grant	3,294,051

Share-based Compensation - Opti

Share-based Compensation - Option activity (Details) - Incentive stock options - 2019 Plan - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Number of Options
Outstanding Beginning Balance		1,000,000
Granted	1,000,000	12,705,949
Outstanding Ending Balance	1,000,000	13,705,949
Exercisable at December 31, 2020		12,455,949
Weighted Average Exercise Price
Outstanding Beginning Balance		$ 0.053525
Granted	$ 0.053525	0.0291
Outstanding Ending Balance	$ 0.053525	0.027736
Exercisable at December 31, 2020		$ 0.024498
Weighted Average Contractual Term in Years
Granted	10 years	10 years
Outstanding Balance	9 years 7 months 6 days	9 years 3 months 26 days
Exercisable at December 31, 2020		9 years 3 months 7 days

Share-based Compensation - Assu

Share-based Compensation - Assumptions (Details)	12 Months Ended
	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate - Minimum	0.29%
Risk-free interest rate - Maximum	1.39%
Dividend yield	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	136.81%
Expected term	5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	171.47%
Expected term	6 years

Share-based Compensation - Rest

Share-based Compensation - Restrictive stock awards (Details) - USD ($)	Mar. 08, 2021	Feb. 17, 2020	Feb. 29, 2020	Dec. 31, 2020
Number of Units
Granted				7,311,904
Exercised and converted to common shares				(5,928,571)
Outstanding at December 31, 2020				1,383,333
Exercisable at December 31, 2020				345,833
Weighted Average Grant Date Fair Value
Granted				$ 0.023
Exercised and converted to common shares				0.014
Outstanding at December 31, 2020				0.060
Exercisable at December 31, 2020				$ 0.060
Value of awards			$ 83,000
Closing stock price			$ 0.014
Stock-based compensation expense				$ 63,000
Restricted stock award
Weighted Average Grant Date Fair Value
Value of awards		$ 5,928,571
Closing stock price				$ 0.06
Stock-based compensation expense				$ 103,000
Mr. Levy | Restricted stock award | Subsequent Events
Weighted Average Grant Date Fair Value
Value of awards	$ 1,383,333

Share-based Compensation - Warr

Share-based Compensation - Warrants (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Number of Options
Outstanding at beginning of period	5,250,000
Granted	2,117,500
Outstanding at end of period	7,367,500	5,250,000
Exercisable at end of period	7,367,500
Weighted Average Exercise Price
Outstanding at beginning of period	$ 0.014000
Granted	0.050720
Outstanding at end of period	$ 0.050720	$ 0.014000
Exercisable at end of period	$ 0.050720
Weighted Average Contractual Term in Years
Granted	3 years 3 months 18 days
Outstanding at December 31,	2 years 18 days	2 years 9 months 22 days
Exercisable at end of period	2 years 18 days
Intrinsic value of vested outstanding warrants	$ 408,000

Share-based Compensation - Addi

Share-based Compensation - Additional information (Details)	Oct. 10, 2020$ / sharesshares	Feb. 17, 2020USD ($)$ / sharesshares	Jul. 31, 2020employeeindividualshares	May 31, 2020employeeindividualshares	Aug. 31, 2019employeeindividualshares	Dec. 31, 2019$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	May 26, 2020shares	May 25, 2020shares	Aug. 28, 2019shares
Share-based Compensation
Aggregate purchase price | $							$ 1,370,000	$ 673,000
Options
Share-based Compensation
Shares awarded							325,000
Vesting percentage							10.00%
2019 Plan
Share-based Compensation
Number of shares reserved for future issuance							17,000,000		17,000,000	2,000,000	2,000,000
Number of shares available for grant							13,705,949
Shares awarded							3,294,051
2019 Plan | Options
Share-based Compensation
Shares awarded							5,000,000
2019 Plan | Executive officer
Share-based Compensation
Number of shares available for grant									500,000		500,000
2019 Long-Term Incentive Plan | Board of Director
Share-based Compensation
Aggregate purchase price | $		$ 40,000
2019 Long-Term Incentive Plan | Board of Director | First grant
Share-based Compensation
Granted		2,857,141
Exercise Price | $ / shares		$ 0.014
Incentive stock options | 2019 Plan
Share-based Compensation
Shares awarded			5,325,000	5,325,000	1,000,000
Number of employees to whom options granted | employee			2	2	2
Number of contractors to whom options granted | individual			1	1	1
Term of options					10 years
Granted						1,000,000	12,705,949
Exercise Price | $ / shares						$ 0.053525	$ 0.0291
Intrinsic value | $							$ 681,000
Un-recognized share-based compensation expense | $							$ 72,000
Period of recognition of stock based compensation expense							12 years
Incentive stock options | 2019 Plan | First grant
Share-based Compensation
Vesting percentage					50.00%
Incentive stock options | 2019 Plan | First anniversary
Share-based Compensation
Vesting percentage					50.00%
Restricted stock award
Share-based Compensation
Shares awarded	666,667
Exercise Price | $ / shares	$ 0.06

Note Payable (Details)

Note Payable (Details) - USD ($)	May 28, 2020	Apr. 22, 2020
PPP loan
Debt Instrument [Line Items]
Loan amount		$ 147,300
Term of the loan		2 years
Interest rate		1.00%
Deferred period		6 months
Prepayment penalties		$ 0
EIDL loan program
Debt Instrument [Line Items]
Term of the loan	30 years
Interest rate	3.75%
Borrowing capacity	$ 260,500
Monthly payment	1,270
Loan advance	$ 8,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details)	Dec. 24, 2020USD ($)security$ / sharesshares
Short-term Debt [Line Items]
Number of securities purchase agreement entered into by company | security	2
Common stock warrants
Short-term Debt [Line Items]
Number of shares called by warrants | shares	312,500
Exercise price of warrants	$ 0.08
6% Secured Convertible Promissory Note
Short-term Debt [Line Items]
Principal amount of debt | $	$ 100,000
Interest rate	6.00%
Conversion price (in dollars per share)	$ 0.08

Warrant Liability (Details)

Warrant Liability (Details)	Dec. 24, 2020shares	Mar. 18, 2020shares	Nov. 06, 2019USD ($)$ / sharesshares	Sep. 10, 2019USD ($)$ / sharesshares	Dec. 31, 2020USD ($)Y$ / sharesshares	Dec. 31, 2019USD ($)shares	Nov. 06, 2020USD ($)$ / sharesshares	Mar. 20, 2020$ / shares
Class of Warrant or Right [Line Items]
Warrants Outstanding | shares					7,367,500	5,250,000
Changes in fair value of warrant liability | $					$ (2,000)	$ 1,000
Warrant Liability
Class of Warrant or Right [Line Items]
Warrants Outstanding | shares			4,000,000	1,250,000	7,055,000	5,250,000	1,805,000
Warrants Fair value per share			$ 0.01085	$ 0.01091			$ 0.03671
Warrants Fair value | $			43,000	14,000	123,000	56,000	65,000
Changes in fair value of warrant liability | $					$ (2,000)
Exercise Price | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.08
Exercise Price | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.04
Exercise Price | Warrants Issuance on September 10, 2019, Expiring on September 10, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Exercise Price | Warrants Issuance on November 6, 2019, Expiring on November 6, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Exercise Price | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.08
Exercise Price | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023
Class of Warrant or Right [Line Items]
Warrants Fair value					0.04
Exercise Price | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Exercise Price | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Exercise Price | Warrants Issuance On September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Exercise Price | Warrants Issuance On November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Stock Price | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.08
Stock Price | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.04
Stock Price | Warrants Issuance on September 10, 2019, Expiring on September 10, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Stock Price | Warrants Issuance on November 6, 2019, Expiring on November 6, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Stock Price | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.08
Stock Price | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023
Class of Warrant or Right [Line Items]
Warrants Fair value					0.04
Stock Price | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Stock Price | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Stock Price | Warrants Issuance On September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Stock Price | Warrants Issuance On November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.014
Interest Rate (annual) | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.17
Interest Rate (annual) | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.66
Interest Rate (annual) | Warrants Issuance on September 10, 2019, Expiring on September 10, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					1.61
Interest Rate (annual) | Warrants Issuance on November 6, 2019, Expiring on November 6, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					1.60
Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.17
Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023
Class of Warrant or Right [Line Items]
Warrants Fair value					0.13
Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.13
Interest Rate (annual) | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					1.13
Interest Rate (annual) | Warrants Issuance On September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.0162
Interest Rate (annual) | Warrants Issuance On November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.0162
Volatility (annual) | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					172.54
Volatility (annual) | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					137.41
Volatility (annual) | Warrants Issuance on September 10, 2019, Expiring on September 10, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					139.84
Volatility (annual) | Warrants Issuance on November 6, 2019, Expiring on November 6, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					138.48
Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					172.38
Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023
Class of Warrant or Right [Line Items]
Warrants Fair value					172.38
Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					172.38
Volatility (annual) | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					172.38
Volatility (annual) | Warrants Issuance On September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					1.3747
Volatility (annual) | Warrants Issuance On November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					1.3747
Time to Maturity (Years) | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					3
Time to Maturity (Years) | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					3
Time to Maturity (Years) | Warrants Issuance on September 10, 2019, Expiring on September 10, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					3
Time to Maturity (Years) | Warrants Issuance on November 6, 2019, Expiring on November 6, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					3
Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					2.98
Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					2.21
Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					1.85
Time to Maturity (Years) | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value | Y					1.69
Time to Maturity (Years) | Warrants Issuance On September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value | $					2.70
Time to Maturity (Years) | Warrants Issuance On November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value | $					2.85
Calculated fair value per share | Warrants Issuance on December 24, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.0692188
Calculated fair value per share | Warrants Issuance on March 18, 2020, Expiring on March 18, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.0307299
Calculated fair value per share | Warrants Issuance on September 10, 2019, Expiring on September 10, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.01091
Calculated fair value per share | Warrants Issuance on November 6, 2019, Expiring on November 6, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.1095
Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on December 24, 2020
Class of Warrant or Right [Line Items]
Warrants Fair value					0.0692188
Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on March 18, 2023
Class of Warrant or Right [Line Items]
Warrants Fair value					0.0307299
Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.01091
Calculated fair value per share | Warrants Issuance on December 31, 2020, Expiring on November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.1095
Calculated fair value per share | Warrants Issuance On September 10, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.01045
Calculated fair value per share | Warrants Issuance On November 6, 2022
Class of Warrant or Right [Line Items]
Warrants Fair value					0.01064
Private placement
Class of Warrant or Right [Line Items]
Warrants issued | shares	255,000	1,550,000	4,000,000	1,250,000
Number of shares issued on exercise of Warrants | shares					1
Warrants Fair value per share								$ 0.04
Private placement | Minimum
Class of Warrant or Right [Line Items]
Warrants Fair value per share					$ 0.014
Private placement | Maximum
Class of Warrant or Right [Line Items]
Warrants Fair value per share					$ 0.080

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	May 29, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 24, 2020
Related Party Transaction [Line Items]
Operating losses		$ (2,260,000)	$ (1,924,000)
Cash advances		0	1,345,000
Parents net investment in entity		1,345
Sports Defense LLC
Related Party Transaction [Line Items]
Issuance of common stock for acquisition (in shares)	9,375,000
Mr. Stein, a member of the board of directors
Related Party Transaction [Line Items]
Principal amount of debt					$ 100,000
Mr. Stein, a member of the board of directors | Sports Defense LLC
Related Party Transaction [Line Items]
Issuance of common stock for acquisition (in shares)	3,187,500
Mr. Levy | Sports Defense LLC
Related Party Transaction [Line Items]
Issuance of common stock for acquisition (in shares)	1,546,875
Dr. Jerome Zeldis, a member of the board of directors
Related Party Transaction [Line Items]
Outstanding amount		$ 30,000
Adynxx
Related Party Transaction [Line Items]
Operating losses				$ 612,000,000
Cash advances			$ 1,350,000

Income Taxes - Provision of Inc

Income Taxes - Provision of Income Tax (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
Income tax provision	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Tax Benefit on Stautory Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
U.S. federal statutory rate	21.00%	21.00%
State tax rate, net of federal benefit	5.30%	5.30%
Permanent differences
Non-deductible expenses	(1.27%)	(0.70%)
State tax change	0.00%	0.00%
Change in valuation allowance	(25.03%)	(25.60%)
Income tax provision	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 2,494	$ 2,110
Other	3	2
Total deferred tax assets	2,497	2,112
Valuation allowance	(2,382)	(2,072)
Deferred tax assets, net of valuation allowance	115	40
Deferred tax liabilities:
Property and equipment, net	(115)	(40)
Total deferred tax liabilities	$ (115)	$ (40)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Federal corporate income tax rate	21.00%	21.00%
Federal NOL carryovers	$ 10,000,000	$ 8,000,000
Recorded tax liabilities for uncertain tax positions	0	0
Income tax expense (benefit)	0	0
PENNSYLVANIA
Federal NOL carryovers	$ 10,000,000	$ 7,900,000

Concentration of Risk (Details)

Concentration of Risk (Details)	12 Months Ended
	Dec. 31, 2020customer	Dec. 31, 2019
Total Revenue
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	10.00%	10.00%
Number of major customers	3	4
Accounts Receivable
Concentration Risk [Line Items]
Number of major customers	3	4
Customer One | Total Revenue
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	45.00%	38.00%
Customer One | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	57.00%	0.00%
Customer Two | Total Revenue
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	22.00%	17.00%
Customer Two | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	0.00%	13.00%
Customer Three | Total Revenue
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	11.00%	13.00%
Customer Three | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	0.00%	0.00%
Customer Four | Total Revenue
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue		10.00%
Customer Four | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue	12.00%	34.00%
Customer Five | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue		43.00%
Customer Six | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue		43.00%
Customer Seven | Accounts Receivable
Concentration Risk [Line Items]
Percentage of accounts receivable and total revenue		43.00%

Subsequent Events (Details)

Subsequent Events (Details)

Mar. 11, 2021USD ($)M$ / sharesshares

Mar. 08, 2021$ / sharesshares

Oct. 10, 2020$ / shares

Aug. 14, 2020USD ($)shares

Mar. 20, 2020USD ($)$ / sharesshares

Sep. 10, 2019$ / sharesshares

Mar. 31, 2021USD ($)$ / sharesshares

Dec. 24, 2020USD ($)$ / sharesshares

Mar. 31, 2020USD ($)

Mar. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 31, 2019USD ($)

Mar. 04, 2021USD ($)

Sep. 10, 2018$ / shares

Subsequent Events

Proceeds received from convertible notes

$ 100,000

$ 0

Aggregate purchase price

$ 1,370,000

$ 673,000

Number of awards granted | shares

7,311,904

Restricted stock award

Subsequent Events

Exercise Price | $ / shares

$ 0.06

Private placement

Subsequent Events

Number of shares called by warrants | shares

1

Exercise price of warrants | $ / shares

$ 0.04

Issuance of common stock (in shares) | shares

6,585,000

15,500,000

3,269,500

4,437,500

Issue price per share (in dollars per share) | $ / shares

$ 0.04

$ 0.053525

$ 0.08

$ 0.014

Aggregate purchase price

$ 395,100

$ 620,000

$ 355,000

Private placement | Maximum

Subsequent Events

Exercise price of warrants | $ / shares

$ 0.080

Auctus Note

Subsequent Events

Proceeds received from convertible notes

$ 1,337,000

Interest rate

12.00%

Number of calendar days after which the note may not be paid in whole or in part

180 days

Subsequent Events | Dr. Jerome Zeldis, a member of the board of directors | 2019 Plan

Subsequent Events

Exercise Price | $ / shares

$ 0.06

Subsequent Events | Dr. Jerome Zeldis, a member of the board of directors | 2019 Plan | Maximum

Subsequent Events

Number of options granted | shares

666,667

Subsequent Events | Mr. Steven Glassman, a member of the board of directors | 2019 Plan

Subsequent Events

Exercise Price | $ / shares

$ 0.08

Subsequent Events | Mr. Steven Glassman, a member of the board of directors | 2019 Plan | Maximum

Subsequent Events

Number of options granted | shares

500,000

Subsequent Events | Restricted stock award | Mr. Levy

Subsequent Events

Number of awards granted | shares

1,383,333

Subsequent Events | Private placement

Subsequent Events

Issuance of common stock (in shares) | shares

3,562,500

3,562,500

Issue price per share (in dollars per share) | $ / shares

$ 0.08

$ 0.08

Aggregate purchase price

$ 285,000

$ 285,000

Subsequent Events | Auctus Note

Subsequent Events

Principal amount of debt

$ 1,500,000

Proceeds received from convertible notes

$ 1,337,000

Term of the loan

1 year

Number of months interest guaranteed and deemed to be earned in full as of the Issuance Date | M

12

Increase in interest rate if the Company fails to pay any amount when due (as a percent)

$ 180,000

Increase in interest rate if the Company fails to pay any amount when due (as a percent)

16.00%

Prepayment period, number of calendar days

180 days

Prepayment penalty (as a percent)

110.00%

Threshold beneficial ownership (as a percent)

4.99%

Threshold calendar days to be quoted or listed in stock exchanges

120 days

Threshold calendar days to file registration statement

30 days

Threshold calendar days to cause the registration statement to become effective

150 days

Number of warrants issued | shares

2

Term of the warrants issued

5 years

Total cash fee paid to placement agent

$ 120,000

Percentage of principal amount paid as placement agent fees (as a percent)

8.00%

Aggregate purchase price

$ 0.10

Loan amount

$ 127,000

Subsequent Events | Auctus Note | First Auctus Warrant

Subsequent Events

Number of shares called by warrants | shares

6,000,000

Exercise price of warrants | $ / shares

$ 0.125

Subsequent Events | Auctus Note | Second Auctus Warrant

Subsequent Events

Number of warrants issued | shares

5,000,000

Exercise price of warrants | $ / shares

$ 0.15

Subsequent Events | Paycheck Protection Program, Phase II

Subsequent Events

Loan amount

$ 127,000